U.S. patent application number 17/680843 was filed with the patent office on 2022-08-18 for chimeric gene constructs for generation of fluorescent transgenic ornamental fish.
This patent application is currently assigned to National University of Singapore. The applicant listed for this patent is National University of Singapore. Invention is credited to Zhiyuan GONG, Jiangyan HE, Bensheng JU, Toong Jin LAM, Yanfei XU, Tie YAN.
Application Number | 20220256819 17/680843 |
Document ID | / |
Family ID | |
Filed Date | 2022-08-18 |
United States Patent
Application |
20220256819 |
Kind Code |
A1 |
GONG; Zhiyuan ; et
al. |
August 18, 2022 |
CHIMERIC GENE CONSTRUCTS FOR GENERATION OF FLUORESCENT TRANSGENIC
ORNAMENTAL FISH
Abstract
Four zebrafish gene promoters, which are skin specific, muscle
specific, skeletal muscle specific and ubiquitously expressed
respectively, were isolated and ligated to the 5' end of the EGFP
gene. When the resulting chimeric gene constructs were introduced
into zebrafish, the transgenic zebrafish emit green fluorescence
under a blue light or ultraviolet light according to the
specificity of the promoters used. Thus, new varieties of
ornamental fish of different fluorescence patterns, e.g., skin
fluorescence, muscle fluorescence, skeletal muscle-specific and/or
ubiquitous fluorescence, are developed.
Inventors: |
GONG; Zhiyuan; (Singapore,
SG) ; HE; Jiangyan; (Cleveland, OH) ; JU;
Bensheng; (Singapore, SG) ; LAM; Toong Jin;
(Singapore, SG) ; XU; Yanfei; (Chicago, IL)
; YAN; Tie; (Singapore, SG) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
National University of Singapore |
Singapore |
|
SG |
|
|
Assignee: |
National University of
Singapore
Singapore
SG
|
Appl. No.: |
17/680843 |
Filed: |
February 25, 2022 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15674798 |
Aug 11, 2017 |
11259509 |
|
|
17680843 |
|
|
|
|
13738704 |
Jan 10, 2013 |
9763430 |
|
|
15674798 |
|
|
|
|
13334444 |
Dec 22, 2011 |
8378169 |
|
|
13738704 |
|
|
|
|
11749032 |
May 15, 2007 |
8153858 |
|
|
13334444 |
|
|
|
|
10605708 |
Oct 21, 2003 |
7834239 |
|
|
11749032 |
|
|
|
|
09913898 |
Oct 3, 2001 |
7135613 |
|
|
PCT/SG99/00079 |
Jul 16, 1999 |
|
|
|
10605708 |
|
|
|
|
International
Class: |
A01K 67/027 20060101
A01K067/027; C07K 14/435 20060101 C07K014/435; C12N 15/85 20060101
C12N015/85; G01N 33/74 20060101 G01N033/74 |
Foreign Application Data
Date |
Code |
Application Number |
Feb 18, 1999 |
SG |
9900811-2 |
Jul 14, 1999 |
SG |
9903367-2 |
Claims
1-41. (canceled)
42. A transgenic fish comprising a chimeric gene comprising a
cytokeratin (CK) gene promoter operably linked to a fluorescence
gene encoding a fluorescent protein, wherein the transgenic fish
expresses the fluorescent protein at a level sufficient that the
transgenic fish fluoresces upon exposure to sunlight.
43. The transgenic fish of claim 42, wherein the CK gene promoter
is expressed in skin epithelia of the fish,
44. The transgenic fish of claim 42, wherein the CK gene promoter
comprises the gene sequence set forth in SEQ ID NO: 7.
45. The transgenic fish of claim 42, wherein the fluorescence gene
is under control of the CK gene promoter.
46. The transgenic fish of claim 42, wherein the transgenic fish
contains the promoter in germ cells and/or in somatic cells and
which is capable of breeding with either a the transgenic fish or a
non-transgenic fish to produce viable and fertile transgenic
progeny.
47. The transgenic fish of claim 42, wherein the transgenic fish or
a progeny thereof emits green fluorescence when the whole
transgenic fish or the progeny thereof is exposed to a blue or
ultraviolet light.
48. The transgenic fish of claim 42, wherein the transgenic fish or
a progeny thereof expresses a Green Fluorescent Protein.
49. The transgenic fish of claim 42, wherein the transgenic fish or
a progeny thereof expresses an Enhanced Green Fluorescent
Protein.
50. The transgenic fish of claim 42, wherein the transgenic fish or
a progeny thereof expresses a Blue Fluorescent Protein.
51. The transgenic fish of claim 42, wherein the transgenic fish or
a progeny thereof expresses an Enhanced Blue Fluorescent
Protein.
52. The transgenic fish of claim 42, wherein the transgenic fish or
a progeny thereof expresses an Enhanced Yellow Fluorescent
Protein.
53. The transgenic fish of claim 42, wherein the transgenic fish or
a progeny thereof expresses a Cyan Fluorescent Protein.
54. The transgenic fish of claim 42, wherein the transgenic fish or
a progeny thereof expresses an Enhanced Cyan Fluorescent
Protein.
55. The transgenic fish of claim 42, wherein the transgenic fish or
a progeny thereof expresses more than one fluorescent proteins.
56. The transgenic fish of claim 42, wherein the transgenic fish is
selected from a group consisting of medaka, goldfish, carp, koi,
loach, tilapia, glassfish, catfish, angel fish, discus, eel, tetra,
goby, gourami, guppy, Xiphophorus (swordtail), hatchet fish, Molly
fish and Pangasius.
57. The transgenic fish of claim 42, wherein the transgenic fish is
a zebrafish.
58. A transgenic fish whose genome comprises a transgene comprising
a promoter consisting of the nucleic acid sequence set forth by SEQ
ID NO: 7, wherein the promoter is operably linked to a fluorescence
gene encoding a fluorescent protein, wherein the transgene fish is
capable of breeding to produce viable and fertile transgenic
progeny that express the fluorescence protein when exposed to
sunlight.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This is a continuation of co-pending application Ser. No.
09/913,898, filed Oct. 3, 2001, which is a nationalization of PCT
application WO 00/49150 filed Jul. 16, 1999, claiming priority over
a Singapore application filed Jul. 14, 1999, and an earlier
Singapore application, Serial No. 9900811-2, filed Feb. 18, 1999,
all of which are incorporated herein by reference in their
entirety.
BACKGROUND OF INVENTION
[0002] This invention relates to fish gene promoters and chimeric
gene constructs with these promoters for generation of transgenic
fish, particularly fluorescent transgenic ornamental fish.
[0003] Transgenic technology involves the transfer of a foreign
gene into a host organism enabling the host to acquire a new and
inheritable trait. The technique was first developed in mice by
Gordon et al. (1980). They injected foreign DNA into fertilized
eggs and found that some of the mice developed from the injected
eggs retained the foreign DNA. Applying the same technique,
Palmiter et al. (1982) have introduced a chimeric gene containing a
rat growth hormone gene under a mouse heavy metal-inducible gene
promoter and generated the first batch of genetically engineered
supermice, which are almost twice as large as non-transgenic
siblings. This work has opened a promising avenue in using the
transgenic approach to provide to animals new and beneficial traits
for livestock husbandry and aquaculture.
[0004] In addition to the stimulation of somatic growth for
increasing the gross production of animal husbandry and
aquaculture, transgenic technology also has many other potential
applications. First of all, transgenic animals can be used as
bioreactors to produce commercially useful compounds by expression
of a useful foreign gene in milk or in blood. Many pharmaceutically
useful protein factors have been expressed in this way. For
example, human al-antitrypsin, which is commonly used to treat
emphysema, has been expressed at a concentration as high as 35
mg/ml (10% of milk proteins) in the milk of transgenic sheep
(Wright et al., 1991). Similarly, the transgenic technique can also
be used to improve the nutritional value of milk by selectively
increasing the levels of certain valuable proteins such as caseins
and by supplementing certain new and useful proteins such as
lysozyme for antimicrobial activity (Maga and Murray, 1995).
Second, transgenic mice have been widely used in medical research,
particularly in the generation of transgenic animal models for
human disease studies (Lathe and Mullins, 1993). More recently, it
has been proposed to use transgenic pigs as organ donors for
xenotransplantation by expressing human regulators of complement
activation to prevent hyperacute rejection during organ
transplantation (Cozzi and White, 1995). The development of disease
resistant animals has also been tested in transgenic mice (e.g.
Chen et al., 1988).
[0005] Fish are also an intensive research subject of transgenic
studies. There are many ways of introducing a foreign gene into
fish, including: microinjection (e.g. Zhu et al., 1985; Du et al.,
1992), electroporation (Powers et al., 1992), sperm-mediated gene
transfer (Khoo et al., 1992; Sin et al., 1993), gene bombardment or
gene gun (Zelemin et al., 1991), liposome-mediated gene transfer
(Szelei et al., 1994), and the direct injection of DNA into muscle
tissue (Xu et al., 1999). The first transgenic fish report was
published by Zhu et al. (1985) using a chimeric gene construct
consisting of a mouse metallothionein gene promoter and a human
growth hormone gene. Most of the early transgenic fish studies have
concentrated on growth hormone gene transfer with an aim of
generating fast growing "superfish". A majority of early attempts
used heterologous growth hormone genes and promoters and failed to
produce gigantic superfish (e.g. Chourrout et al., 1986; Penman et
al., 1990; Brem et al., 1988; Gross et al., 1992). But enhanced
growth of transgenic fish has been demonstrated in several fish
species including Atlantic salmon, several species of Pacific
salmons, and loach (e.g. Du et al., 1992; Delvin et al., 1994,
1995; Tsai et al., 1995).
[0006] The zebrafish, Danio rerio, is a new model organism for
vertebrate developmental biology. As an experimental model, the
zebrafish offers several major advantages such as easy availability
of eggs and embryos, tissue clarity throughout embryogenesis,
external development, short generation time and easy maintenance of
both the adult and the young. Transgenic zebrafish have been used
as an experimental tool in zebrafish developmental biology.
However, despite the fact that the first transgenic zebrafish was
reported a decade ago (Stuart et al., 1988), most transgenic
zebrafish work conducted so far used heterologous gene promoters or
viral gene promoters: e.g. viral promoters from SV40 (simian virus
40) and RSV (Rous sarcoma virus) (Stuart et al., 1988, 1990; Bayer
and Campos-Ortega, 1992), a carp actin promoter (Liu et al., 1990),
and mouse homeobox gene promoters (Westerfield et al., 1992). As a
result, the expression pattern of a transgene in many cases is
variable and unpredictable.
[0007] GFP (green fluorescent protein) was isolated from a jelly
fish, Aqueous victoria. The wild type GFP emits green fluorescence
at a wavelength of 508 nm upon stimulation with ultraviolet light
(395 nm). The primary structure of GFP has been elucidated by
cloning of its cDNA and genomic DNA (Prasher et al., 1992). A
modified GFP, also called EGFP (Enhanced Green Fluorescent Protein)
has been generated artificially and it contains mutations that
allow the protein to emit a stronger green light and its coding
sequence has also been optimized for higher expression in mammalian
cells based on preferable human codons. As a result, EGFP
fluorescence is about 40 times stronger than the wild type GFP in
mammalian cells (Yang et al., 1996). GFP (including EGFP) has
become a popular tool in cell biology and transgenic research. By
fusing GFP with a tested protein, the GFP fusion protein can be
used as an indicator of the subcellular location of the tested
protein (Wang and Hazelrigg, 1994). By transformation of cells with
a functional GFP gene, the GFP can be used as a marker to identify
expressing cells (Chalfie et al., 1994). Thus, the GFP gene has
become an increasingly popular reporter gene for transgenic
research as GFP can be easily detected by a non-invasive
approach.
[0008] The GFP gene (including EGFP gene) has also been introduced
into zebrafish in several previous reports by using various gene
promoters, including Xenopus elongation factor 1.alpha.
enhancer-promoter (Amsterdam et al., 1995, 1996), rat myosin
light-chain enhancer (Moss et al., 1996), zebrafish GATA-1 and
GATA-3 promoters (Meng et al., 1997; Long et al., 1997), zebrafish
.alpha.- and .beta.-actin promoters (Higashijima et al., 1997), and
tilapia insulin-like growth factor I promoter (Chen et al., 1998).
All of these transgenic experiments aim at either developing a GFP
transgenic system for gene expression analysis or at testing
regulatory DNA elements in gene promoters.
SUMMARY OF INVENTION
[0009] It is a primary objective of the invention to clone fish
gene promoters that are constitutive (ubiquitous), or that have
tissue specificity such as skin specificity or muscle specificity
or that are inducible by a chemical substance, and to use these
promoters to develop effective gene constructs for production of
transgenic fish.
[0010] It is another objective of the invention to develop
fluorescent transgenic ornamental fish using these gene constructs.
By applying different gene promoters, tissue-specific, inducible
under different environmental conditions, or ubiquitous, to drive
the GFP gene, GFP could be expressed in different tissues or
ubiquitously. Thus, these transgenic fish may be skin fluorescent,
muscle fluorescent, ubiquitously fluorescent, or inducibly
fluorescent. These transgenic fish may be used for ornamental
purposes, for monitoring environmental pollution, and for basic
studies such as recapitulation of gene expression programs or
monitoring cell lineage and cell migration. These transgenic fish
may be used for cell transplantation and nuclear transplantation or
fish cloning.
[0011] Other objectives, features and advantages of the present
invention will become apparent from the detailed description which
follows, or may be learned by practice of the invention.
[0012] Four zebrafish gene promoters of different characteristics
were isolated and four chimeric gene constructs containing a
zebrafish gene promoter and EGFP DNA were made: pCK-EGFP,
pMCK-EGFP, pMLC2f-EGFP and pARP-EGFP. The first chimeric gene
construct, pCK-EGFP, contains a 2.2 kbp polynucleotide comprising a
zebrafish cytokeratin (CK) gene promoter which is specifically or
predominantly expressed in skin epithelia. The second one,
pMCK-EGFP, contains a 1.5 kbp polynucleotide comprising a
muscle-specific promoter from a zebrafish muscle creatine kinase
(MCK) gene and the gene is only expressed in the muscle tissue. The
third construct, pMLC2f-EGFP contains a 2.2 kpb polynucleotide
comprising a strong skeletal muscle-specific promoter from the fast
skeletal muscle isoform of the myosin light chain 2 (MLC2f) gene
and is expressed specifically or predominantly in skeletal muscle.
The fourth chimeric gene construct, pARP-EGFP, contains a strong
and ubiquitously expressed promoter from a zebrafish acidic
ribosomal protein (ARP) gene. These four chimeric gene constructs
have been introduced into zebrafish at the one cell stage by
microinjection. In all cases, the GFP expression patterns were
consistent with the specificities of the promoters. GFP was
predominantly expressed in skin epithelia with pCK-EGFP,
specifically expressed in muscles with pMCK-EGFP, specifically
expressed in skeletal muscles with pMLC2f-EGFP and ubiquitously
expressed in all tissues with pARP-EGFP.
[0013] These chimeric gene constructs are useful to generate green
fluorescent transgenic fish. The GFP transgenic fish emit green
fluorescence light under a blue or ultraviolet light and this
feature makes the genetically engineered fish unique and attractive
in the ornamental fish market. The fluorescent transgenic fish are
also useful for the development of a biosensor system and as
research models for embryonic studies such as cell lineage, cell
migration, cell and nuclear transplantation etc.
BRIEF DESCRIPTION OF DRAWINGS
[0014] FIGS. 1A-1I are photographs showing expression of CK (FIGS.
1A-1C), MCK (FIGS. 1D-1E), ARP (FIGS. 1F-1G) and MLC2f (FIGS.
1H-1I) mRNAs in zebrafish embryos as revealed by whole mount in
situ hybridization (detailed description of the procedure can be
found in Thisse et al., 1993). (FIG. 1A) A 28 hpf (hour
postfertilization) embryo hybridized with a CK antisense riboprobe.
(FIG. 1B) Enlargement of the mid-part of the embryo shown in FIG.
1A. (FIG. 1C) Cross-section of the embryo in FIG. 1A. (FIG. 1D) A
30 hpf embryo hybridized with an MCK antisense riboprobe. (FIG. 1E)
Cross-section of the embryo in FIG. 1D. (FIG. 1F) A 28 hpf embryo
hybridized with an ARP antisense riboprobe. (FIG. 1G) Cross-section
of the embryo in FIG. 1F. Arrows indicate the planes for
cross-sections and the box in panel A indicates the enlarged region
shown in panel B. (FIG. 1H) Side view of a 22-hpf embryo hybridized
with the MLC2f probe. (FIG. 1I) Transverse section through the
trunk of a stained 24-hpf embryo. SC, spinal cord; N,
notochord.
[0015] FIG. 2A is a digitized image showing distribution of CK, MCK
and ARP mRNAs in adult tissues. Total RNAs were prepared from
selected adult tissues as indicated at the top of each lane and
analyzed by Northern blot hybridization (detailed description of
the procedure can be found in Gong et al., 1992). Three identical
blots were made from the same set of RNAs and hybridized with the
CK, MCK and ARP probes, respectively.
[0016] FIG. 2B is a digitized image showing distribution of MLC2f
mRNA in adult tissues. Total RNAs were prepared from selected adult
tissues as indicated at the top of each lane and analyzed by
Northern blot hybridization (detailed description of the procedure
can be found in Gong et al., 1992). Two identical blots were made
from the same set of RNAs and hybridized with the MLC2f probe and a
ubiquitously expressed .beta.-actin probe, respectively.
[0017] FIG. 3. is a schematic representation of the strategy of
promoter cloning. Restriction enzyme digested genomic DNA was
ligated with a short linker DNA which consists of Oligo 1 and Oligo
2. Nested PCR reactions were then performed: the first round PCR
used linker specific primer L1 and gene specific primers G1, where
G1 is CK1, MCK1, M1 or ARP1 in the described embodiments, and the
second round linker specific primer L2 and gene specific primer G2,
where G2 is CK2, MCK2, M2 or ARP2, respectively in the described
embodiments.
[0018] FIG. 4 is a schematic map of the chimeric gene construct,
pCK-EGFP. The 2.2 kb zebrafish DNA fragment comprising the CK
promoter region is inserted into pEGFP-1 (Clonetech) at the EcoRI
and BamHI site as indicated. In the resulting chimeric DNA
construct, the EGFP gene is under control of the zebrafish CK
promoter. Also shown is the kanamycin/neomycin resistance gene
(Kan.sup.r/Neo.sup.r) in the backbone of the original pEGFP-1
plasmid. The total length of the recombinant plasmid pCK-EGFP is
6.4 kb.
[0019] FIG. 5 is a schematic map of the chimeric gene construct,
pMCK-EGFP. The 1.5 kb zebrafish DNA fragment comprising the MCK
promoter region is inserted into pEGFP-1 (Clonetech) at the EcoRI
and BamHI site as indicated. In the resulting chimeric DNA
construct, the EGFP gene is under control of the zebrafish MCK
promoter. Also shown is the kanamycin/neomycin resistance gene
(Kan.sup.r/Neo.sup.r) in the backbone of the original pEGFP-1
plasmid. The total length of the recombinant plasmid pMCK-EGFP is
5.7 kb.
[0020] FIG. 6 is a schematic map of the chimeric gene construct,
pARP-EGFP. The 2.2 kb zebrafish DNA fragment comprising the ARP
promoter/1st intron region is inserted into pEGFP-1 (Clonetech) at
the EcoRI and BamHI site as indicated. In the resulting chimeric
DNA construct, the EGFP gene is under control of the zebrafish ARP
promoter. Also shown is the kanamycin/neomycin resistance gene
(Kan.sup.r/Neo.sup.r) in the backbone of the original pEGFP-1
plasmid. The total length of the recombinant plasmid pARP-EGFP is
6.4 kb.
[0021] FIG. 7 is a schematic map of the chimeric gene construct,
pMLC2f-EGFP. The 2.0 kb zebrafish DNA fragment comprising the MLC2f
promoter region is inserted into pEGFP-1 (Clonetech) at the HindIII
and BamHI site as indicated. In the resulting chimeric DNA
construct, the EGFP gene is under control of the zebrafish MLC2f
promoter. Also shown is the kanamycin/neomycin resistance gene
(Kan.sup.r/Neo.sup.r) in the backbone of the original pEGFP-1
plasmid. The total length of the recombinant plasmid pMLC2f-EGFP is
6.2 kb.
[0022] FIG. 8 is a photograph of a typical transgenic zebrafish fry
(4 days old) with pCK-EGFP, which emits green fluorescence from
skin epithelia under a blue light.
[0023] FIG. 9 is a photograph of a typical transgenic zebrafish fry
(3 days old) with pMCK-EGFP, which emits green fluorescence from
skeletal muscles under a blue light.
[0024] FIG. 10 is a photograph of a typical transgenic zebrafish
fry (2 days old) with pARP-EGFP, which emits green fluorescence
under a blue light from a variety of cell types such as skin
epithelia, muscle cells, lens, neural tissues, notochord,
circulating blood cells and yolk cells.
[0025] FIGS. 11A-11B. Photographs of a typical transgenic zebrafish
founder with pMLC2f-EGFP (FIG. 11A) and an F1 stable transgenic
offspring (FIG. 11B). Both pictures were taken under an ultraviolet
light (365 nm). The green fluorescence can be better observed under
a blue light with an optimal wavelength of 488 nm.
[0026] FIGS. 12A-12C. Examples of high, moderate and low expression
of GFP in transiently transgenic embryos at 72 hpf. (FIG. 12A) High
expression, GFP expression was detected in essentially 100% of the
muscle fibers in the trunk. (FIG. 12B) Moderate expression, GFP
expression was detected in several bundles of muscle fibers,
usually in the mid-trunk region. (FIG. 12C) Low expression, GFP
expression occurred in dispersed muscle fibers and the number of
GFP positive fibers is usually less than 20 per embryo.
[0027] FIG. 13. Deletion analysis of the MLC2f promoter in
transient transgenic zebrafish embryos. A series of 5'' deletions
of MLC2f-EGFP constructs containing 2011-bp (2-kb), 1338-bp,
873-bp, 283-bp, 77-bp and 3-bp of the MLC2f promoter were generated
by unidirectional deletion using the double-stranded Nested
Deletion Kit from Pharmacia based on the manufacturer"s
instructional manual. Each construct was injected into
approximately 100 embryos and GFP expression was monitored in the
first 72 hours of embryonic development. The level of GFP
expression was classified based on the examples shown in FIGS.
12A-12C. Potential E-boxes and MEF2 binding sites, which are
important for muscle-specific transcription (Schwarz et al., 1993;
Olson et al., 1995), are indicated on the 2011-bp construct.
DETAILED DESCRIPTION
[0028] Gene Constructs. To develop successful transgenic fish with
a predictable pattern of transgene expression, the first step is to
make a gene construct suitable for transgenic studies. The gene
construct generally comprises three portions: a gene promoter, a
structural gene and transcriptional termination signals. The gene
promoter would determine where, when and under what conditions the
structural gene is turned on. The structural gene contains protein
coding portions that determine the protein to be synthesized and
thus the biological function. The structural gene might also
contain intron sequences which can affect mRNA stability or which
might contain transcription regulatory elements. The transcription
termination signals consist of two parts: a polyadenylation signal
and a transcriptional termination signal after the polyadenylation
signal. Both are important to terminate the transcription of the
gene. Among the three portions, selection of a promoter is very
important for successful transgenic study, and it is preferable to
use a homologous promoter (homologous to the host fish) to ensure
accurate gene activation in the transgenic host.
[0029] A promoter drives expression "predominantly" in a tissue if
expression is at least 2-fold, preferably at least 5-fold higher in
that tissue compared to a reference tissue. A promoter drives
expression "specifically" in a tissue if the level of expression is
at least 5-fold, preferably at least 10-fold higher, more
preferably at least 50-fold higher in that tissue than in any other
tissue.
[0030] Recombinant DNA Constructs. Recombinant DNA constructs
comprising one or more of the DNA or RNA sequences described herein
and an additional DNA and/or RNA sequence are also included within
the scope of this invention. These recombinant DNA constructs
usually have sequences which do not occur in nature or exist in a
form that does not occur in nature or exist in association with
other materials that do not occur in nature. The DNA and/or RNA
sequences described as constructs or in vectors above are "operably
linked" with other DNA and/or RNA sequences. DNA regions are
operably linked when they are functionally related to each other.
For example, DNA for a presequence or secretory leader is operably
linked to DNA for a polypeptide if it is expressed as part of a
preprotein which participates in the secretion of the polypeptide;
a promoter is operably linked to a coding sequence if it controls
the transcription of the coding sequence; a ribosome binding site
is operably linked to a coding sequence if it is positioned so as
to permit translation. Generally, operably linked means contiguous
(or in close proximity to) and, in the case of secretory leaders,
contiguous and in reading phase.
[0031] The sequences of some of the DNAs, and the corresponding
proteins encoded by the DNA, which are useful in the invention are
set forth in the attached Sequence Listing.
[0032] The complete cytokeratin (CK) cDNA sequence is shown in SEQ
ID NO:1, and its deduced amino acid sequence is shown in SEQ ID
NO:2. The binding sites of the gene specific primers for promoter
amplification, CK1 and CK2, are indicated. The extra nucleotides
introduced into CK2 for generation of a restriction site are shown
as a misc_feature in the primer sequence SEQ ID NO:11. A potential
polyadenylation signal, AATAAA, is indicated in SEQ ID NO:1.
[0033] The complete muscle creatine kinase (MCK) cDNA sequence is
shown in SEQ ID NO:3, and its deduced amino acid sequence is shown
in SEQ ID NO:4. The binding sites of the gene specific primers for
promoter amplification, MCK1 and MCK2, are indicated. The extra
nucleotides introduced into MCK1 and MCK2 for generation of
restriction sites are shown as a misc_feature in the primer
sequences SEQ ID NOS:12 and 13, respectively. A potential
polyadenylation signal, AATAAA, is indicated in SEQ ID NO:3.
[0034] The complete fast skeletal muscle isoform of myosin light
chain 2 (MLC2f) cDNA sequence is shown in SEQ ID NO:20, and its
deduced amino acid sequence is shown in SEQ ID NO:21. The binding
sites of the gene-specific primers for promoter amplification, M1
and M2, are indicated. Two potential polyadenylation signals,
AATAAA, are shown as a misc_feature in SEQ ID NO:20.
[0035] The complete acidic ribosomal protein P0 (ARP) cDNA sequence
is shown in SEQ ID NO:5, and its deduced amino acid sequence is
shown in SEQ ID NO:6. The binding sites of the gene specific
primers for promoter amplification, ARP1 and ARP2, are indicated.
The extra nucleotides introduced into ARP2 for generation of a
restriction site are shown as a misc_feature in the primer sequence
SEQ ID NO:15. A potential polyadenylation signal, AATAAA, is
indicated in SEQ ID NO:5.
[0036] SEQ ID NO:7 shows the complete sequence of the CK promoter
region. A putative TATA box is shown, and the 3' nucleotides
identical to the 5' CK cDNA sequence are shown as a misc_feature.
The binding site of the second gene specific primer, CK2, is shown.
The introduced BamHI site is indicated as a misc_feature in the
primer sequence SEQ ID NO:11.
[0037] SEQ ID NO:8 shows the complete sequence of the MCK promoter
region. A putative TATA box is shown, and the 3' nucleotides
identical to the 5' MCK cDNA sequence are shown as a misc_feature
in SEQ ID NO:8. The binding site of the second gene specific
primer, MCK2, is shown. The introduced BamHI site is indicated as a
misc_feature in the primer sequence SEQ ID NO:13.
[0038] SEQ ID NO:22 shows the complete sequence of the MLC2f
promoter region. A putative TATA box is shown, and the 3'
nucleotides identical to the 5' MLC2f cDNA sequence are shown as a
misc_feature. The binding site of the second gene-specific primer,
M2, is shown. Potential muscle-specific cis-elements, E-boxes and
MEF2 binding sites, are also shown. The proximal 1-kb region of the
MLC2f promoter was recently published (Xu et al., 1999).
[0039] SEQ ID NO:9 shows the complete sequence of the ARP promoter
region including the first intron. The first intron is shown, and
the 3' nucleotides identical to the 5' ARP cDNA sequence are shown
as misc_features. No typical TATA box is found. The binding site of
the second gene specific primer, ARP2, is shown. The introduced
BamHI site is indicated as a misc_feature in the primer sequence
SEQ ID NO:15.
[0040] Specifically Exemplified Polypeptides/DNA. The present
invention contemplates use of DNA that codes for various
polypeptides and other types of DNA to prepare the gene constructs
of the present invention. DNA that codes for structural proteins,
such as fluorescent peptides including GFP, EGFP, BFP, EBFP, YFP,
EYFP, CFP, ECFP and enzymes (such as luciferase,
.beta.-galactosidase, chloramphenicol acetyltransferase, etc.), and
hormones (such as growth hormone etc.), are useful in the present
invention. More particularly, the DNA may code for polypeptides
comprising the sequences exemplified in SEQ ID NOS:2, 4, 6 and 21.
The present invention also contemplates use of particular DNA
sequences, including regulatory sequences, such as promoter
sequences shown in SEQ ID NOS: 7, 8, 9 and 22 or portions thereof
effective as promoters. Finally, the present invention also
contemplates the use of additional DNA sequences, described
generally herein or described in the references cited herein, for
various purposes.
[0041] Chimeric Genes. The present invention also encompasses
chimeric genes comprising a promoter described herein operatively
linked to a heterologous gene. Thus, a chimeric gene can comprise a
promoter of a zebrafish operatively linked to a zebrafish
structural gene other than that normally found linked to the
promoter in the genome. Alternatively, the promoter can be
operatively linked to a gene that is exogenous to a zebrafish, as
exemplified by the GFP and other genes specifically exemplified
herein. Furthermore, a chimeric gene can comprise an exogenous
promoter linked to any structural gene not normally linked to that
promoter in the genome of an organism.
[0042] Variants of Specifically Exemplified Polypeptide. DNA that
codes for variants of the specifically exemplified polypeptides are
also encompassed by the present invention. Possible variants
include allelic variants and corresponding polypeptides from other
organisms, particularly other organisms of the same species, genus
or family. The variants may have substantially the same
characteristics as the natural polypeptides. The variant
polypeptide will possess the primary property of concern for the
polypeptide. For example, the polypeptide will possess one or more
or all of the primary physical (e.g., solubility) and/or biological
(e.g., enzymatic activity, physiologic activity or fluorescence
excitation or emission spectrum) properties of the reference
polypeptide. DNA of the structural genes of the present invention
will encode a protein that produces a fluorescent or
chemiluminescent light under conditions appropriate to the
particular polypeptide in one or more tissues of a fish. Preferred
tissues for expression are skin, muscle, eye and bone.
[0043] Substitutions, Additions and Deletions. As possible variants
of the above specifically exemplified polypeptides, the polypeptide
may have additional individual amino acids or amino acid sequences
inserted into the polypeptide in the middle thereof and/or at the
N-terminal and/or C-terminal ends thereof so long as the
polypeptide possesses the desired physical and/or biological
characteristics. Likewise, some of the amino acids or amino acid
sequences may be deleted from the polypeptide so long as the
polypeptide possesses the desired physical and/or biochemical
characteristics. Amino acid substitutions may also be made in the
sequences so long as the polypeptide possesses the desired physical
and biochemical characteristics. DNA coding for these variants can
be used to prepare gene constructs of the present invention.
[0044] Sequence Identity. The variants of polypeptides or
polynucleotides contemplated herein should possess more than 75%
sequence identity (sometimes referred to as homology), preferably
more than 85% identity, most preferably more than 95% identity,
even more preferably more than 98% identity to the naturally
occurring and/or specifically exemplified sequences or fragments
thereof described herein. To determine this homology, two sequences
are aligned so as to obtain a maximum match using gaps and
inserts.
[0045] Two sequences are said to be "identical" if the sequence of
residues is the same when aligned for maximum correspondence as
described below. The term "complementary" applies to nucleic acid
sequences and is used herein to mean that the sequence is
complementary to all or a portion of a reference polynucleotide
sequence.
[0046] Optimal alignment of sequences for comparison can be
conducted by the local homology algorithm of Smith and Waterman
(1981), by the homology alignment method of Needleman and Wunsch
(1970), by the search for similarity method of Pearson and Lippman
(1988), or the like. Computer implementations of the above
algorithms are known as part of the Genetics Computer Group (GCG)
Wisconsin Genetics Software Package (GAP, BESTFIT, BLASTA, FASTA
and TFASTA), 575 Science Drive, Madison, Wis. These programs are
preferably run using default values for all parameters.
[0047] "Percentage of sequence identity" is determined by comparing
two optimally aligned sequences over a comparison window, wherein
the portion of the sequence in the comparison window may comprise
additions or deletions (i.e. "gaps") as compared to the reference
sequence for optimal alignment of the two sequences being compared.
The percentage identity is calculated by determining the number of
positions at which the identical residue occurs in both sequences
to yield the number of matched positions, dividing the number of
matched positions by the total number of positions in the window
and multiplying the result by 100 to yield the percentage of
sequence identity. Total identity is then determined as the average
identity over all of the windows that cover the complete query
sequence.
[0048] Fragments of Polypeptide. Genes which code for fragments of
the full length polypeptides such as proteolytic cleavage fragments
which contain at least one, and preferably all, of the above
physical and/or biological properties are also encompassed by the
present invention.
[0049] DNA and RNA. The invention encompasses DNA that codes for
any one of the above polypeptides including, but not limited to,
those shown in SEQ ID NOS:2, 4, 6 and 21 including fusion
polypeptides, variants and fragments thereof. The sequence of
certain particularly useful cDNAs which encode polypeptides are
shown in SEQ ID NOS:1, 3, 5 and 20. The present invention also
includes cDNA as well as genomic DNA containing or comprising the
requisite nucleotide sequences as well as corresponding RNA and
antisense sequences.
[0050] Cloned DNA within the scope of the invention also includes
allelic variants of the specific sequences presented in the
attached Sequence Listing. An "allelic variant" is a sequence that
is a variant from that of the exemplified nucleotide sequence, but
represents the same chromosomal locus in the organism. In addition
to those which occur by normal genetic variation in a population
and perhaps fixed in the population by standard breeding methods,
allelic variants can be produced by genetic engineering methods. A
preferred allelic variant is one that is found in a naturally
occurring organism, including a laboratory strain. Allelic variants
are either silent or expressed. A silent allele is one that does
not affect the phenotype of the organism. An expressed allele
results in a detectable change in the phenotype of the trait
represented by the locus.
[0051] A nucleic acid sequence "encodes" or "codes for" a
polypeptide if it directs the expression of the polypeptide
referred to. The nucleic acid can be DNA or RNA. Unless otherwise
specified, a nucleic acid sequence that encodes a polypeptide
includes the transcribed strand, the hnRNA and the spliced RNA or
the DNA representative of the mRNA. An "antisense" nucleic acid is
one that is complementary to all or part of a strand representative
of mRNA, including untranslated portions thereof.
[0052] Degenerate Sequences. In accordance with degeneracy of
genetic code, it is possible to substitute at least one base of the
base sequence of a gene by another kind of base without causing the
amino acid sequence of the polypeptide produced from the gene to be
changed. Hence, the DNA of the present invention may also have any
base sequence that has been changed by substitution in accordance
with degeneracy of genetic code.
[0053] DNA Modification. The DNA is readily modified by
substitution, deletion or insertion of nucleotides, thereby
resulting in novel DNA sequences encoding the polypeptide or its
derivatives. These modified sequences are used to produce mutant
polypeptide and to directly express the polypeptide. Methods for
saturating a particular DNA sequence with random mutations and also
for making specific site-directed mutations are known in the art;
see e.g. Sambrook et al. (1989).
[0054] Hybridizable Variants. The DNA molecules useful in
accordance with the present invention can comprise a nucleotide
sequence selected from the group consisting of SEQ ID NOS.:1, 3, 5,
7-20 and 22-24 or can comprise a nucleotide sequence that
hybridizes to a DNA molecule comprising the nucleotide sequence of
SEQ ID NOS.:1, 3, 5 or 20 under salt and temperature conditions
providing stringency at least as high as that equivalent to
5.times.SSC and 42.degree. C. and that codes on expression for a
polypeptide that has one or more or all of the above physical
and/or biological properties. The present invention also includes
polypeptides coded for by these hybridizable variants. The
relationship of stringency to hybridization and wash conditions and
other considerations of hybridization can be found in Chapters 11
and 12 of Sambrook et al (1989). The present invention also
encompasses functional promoters which hybridize to SEQ ID NOS:7,
8, 9 or 22 under the above-described conditions. DNA molecules of
the invention will preferably hybridize to reference sequences
under more stringent conditions allowing the degree of mismatch
represented by the degrees of sequence identity enumerated above.
The present invention also encompasses functional primers or linker
oligonucleotides set forth in SEQ ID NOS:10-19 and 23-24 or larger
primers comprising these sequences, or sequences which hybridize
with these sequences under the above-described conditions. The
primers usually have a length of 10-50 nucleotides, preferably
15-35 nucleotides, more preferably 18-30 nucleotides.
[0055] Vectors. The invention is further directed to a replicable
vector containing cDNA that codes for the polypeptide and that is
capable of expressing the polypeptide.
[0056] The present invention is also directed to a vector
comprising a replicable vector and a DNA sequence corresponding to
the above described gene inserted into said vector. The vector may
be an integrating or nonvector depending on its intended use and is
conveniently a plasmid.
[0057] Transformed Cells. The invention further relates to a
transformed cell or microorganism containing cDNA or a vector which
codes for the polypeptide or a fragment or variant thereof and that
is capable of expressing the polypeptide.
[0058] Expression Systems Using Vertebrate Cells. Interest has been
great in vertebrate cells, and propagation of vertebrate cells in
culture (tissue culture) has become a routine procedure. Examples
of vertebrate host cell lines useful in the present invention
preferably include cells from any of the fish described herein.
Expression vectors for such cells ordinarily include (if necessary)
an origin of replication, a promoter located upstream from the gene
to be expressed, along with a ribosome-binding site, RNA splice
site (if introngenomic DNA is used or if an intron is necessary to
optimize expression of a cDNA), a polyadenylation site, and a
transcription termination sequence.
EXAMPLES
[0059] The following examples are provided by way of illustration
only and not by way of limitation. Those of skill will readily
recognize a variety of noncritical parameters which can be changed
or modified to yield essentially similar results.
[0060] Example I: Isolation of skin-specific, muscle-specific and
ubiquitously expressed zebrafish cDNA clones. cDNA clones were
isolated and sequenced as described by Gong et al. (1997).
Basically, random cDNA clones were selected from zebrafish
embryonic and adult cDNA libraries and each clone was partially
sequenced by a single sequencing reaction. The partial sequences
were then used to identify the sequenced clones for potential
function and tissue specificity. Of the distinct clones identified
by this approach, four of them were selected: for skin specificity
(clone A39 encoding cytokeratin, CK), for muscle specificity (clone
E146 encoding muscle creatine kinase, MCK), for skeletal muscle
specificity (clone A113 encoding the fast skeletal muscle isoform
of the myosin light chain 2, MLC2f) and for ubiquitous expression
(clone A150 encoding acidic ribosomal protein P0, ARP),
respectively.
[0061] The four cDNA clones were sequenced, and their complete cDNA
sequences with deduced amino acid sequences are shown in SEQ ID
NOS:1, 3, 5, and 20 respectively. A39 encodes a type II basic
cytokeratin and its closest homolog in mammals is cytokeratin 8
(65-68% amino acid identity). E146 codes for the zebrafish MCK and
its amino acid sequence shares .about.87% identity with mammalian
MCKs. A113 encodes the fast skeletal muscle isoform of the myosin
light chain 2. The deduced amino acid sequence of this gene is
highly homologous to other vertebrate fast skeletal muscle MLC2f
proteins (over 80% amino acid identity). The amino acid sequence of
zebrafish ARP deduced from the A150 clone is 87-89% identical to
those of mammalian ARPs.
[0062] To demonstrate their expression patterns, whole mount in
situ hybridization (Thisse et al., 1993) was performed for
developing embryos and Northern blot analyses (Gong et al., 1992)
were carried out for selected adult tissues and for developing
embryos.
[0063] As indicated by whole mount in situ hybridization,
cytokeratin mRNA was specifically expressed in the embryonic
surface (FIGS. 1A-1C) and cross section of in situ hybridized
embryos confirmed that the expression was only in skin epithelia
(FIG. 1C). Ontogenetically, the cytokeratin mRNA appeared before 4
hours post-fertilization (hpf) and it is likely that the
transcription of the cytokeratin gene starts at mid-blastula
transition when the zygotic genome is activated. By in situ
hybridization, a clear cytokeratin mRNA signal was detected in
highly flattened cells of the superficial layer in blastula and the
expression remained in the superficial layer which eventually
developed into skin epithelia including the yolk sac. In adult
tissues, cytokeratin mRNA was predominantly detected in the skin
and also weakly in several other tissues including the eye, gill,
intestine and muscle, but not in the liver and ovary (FIG. 2).
Therefore, the cytokeratin mRNA is predominantly, if not
specifically, expressed in skin cells.
[0064] MCK mRNA was first detected in the first few anterior
somites in 10 somite stage embryos (14 hpf) and at later stages the
expression is specifically in skeletal muscle (FIG. 1D) and in
heart (data not shown). When the stained embryos are
cross-sectioned, the MCK mRNA signal was found exclusively in the
trunk skeletal muscles (FIG. 1E). In adult tissues, MCK mRNA was
detected exclusively in the skeletal muscle (FIG. 2).
[0065] MLC2f mRNA was specifically expressed in fast skeletal
muscle in developing zebrafish embryos (FIGS. 1H-1I). To examine
the tissue distribution of MLC2f mRNA, total RNAs were prepared
from several adult tissues including heart, brain, eyes, gills,
intestine, liver, skeletal muscle, ovary, skin, and testis. MLC2f
mRNA was only detected in the skeletal muscle by Northern analysis;
while .alpha.-actin mRNA was detected ubiquitously in the same set
of RNAs, confirming the validity of the assay (FIG. 2B).
[0066] ARP mRNA was expressed ubiquitously and it is presumably a
maternal mRNA since it is present in the ovary as well as in
embryos at one cell stage. In in situ hybridization experiments, an
intense hybridization signal was detected in most tissues. An
example of a hybridized embryo at 28 hpf is shown in FIG. 1F. In
adults, ARP mRNA was abundantly expressed in all tissues examined
except for the brain where a relatively weak signal was detected
(FIG. 2A). These observations confirmed that the ARP mRNA is
expressed ubiquitously.
[0067] Example II: Isolation of zebrafish gene promoters Four
zebrafish gene promoters were isolated by a linker-mediated PCR
method as described by Liao et al., (1997) and as exemplified by
the diagrams in FIG. 3. The whole procedure includes the following
steps: 1) designing of gene specific primers; 2) isolation of
zebrafish genomic DNA; 3) digestion of genomic DNA by a restriction
enzyme; 4) ligation of a short linker DNA to the digested genomic
DNA; 5) PCR amplification of the promoter region; and 6) DNA
sequencing to confirm the cloned DNA fragment. The following is the
detailed description of these steps.
[0068] 1. Designing of gene specific primers. Gene specific PCR
primers were designed based on the 5' end of the four cDNA
sequences and the regions used for designing the primers are shown
in SEQ ID NOS: 1, 3, 5 and 20.
[0069] The two cytokeratin gene specific primers are: CK1 (SEQ ID
NO: 10)CK2 (SEQ ID NO:11), where the first six nucleotides are for
creation of an EcoRI site to facilitate cloning.
[0070] The two muscle creatine kinase gene specific primers are:
MCK1 (SEQ ID NO:12), where the first five nucleotides are for
creation of an EcoRI site to facilitate cloning.
[0071] MCK2 (SEQ ID NO:13), where the first three nucleotides are
for creation of an EcoRI site to facilitate cloning.
[0072] The two fast skeletal muscle isoform of myosin light chain 2
gene specific primers are: M1 (SEQ ID NO:23) M2 (SEQ ID NO:24) The
two acidic ribosomal protein P0 gene specific primers are: ARP1
(SEQ ID NO:14)ARP2 (SEQ ID NO:15), where the first six nucleotides
are for creation of an EcoRI site to facilitate cloning.
[0073] 2. Isolation of zebrafish genomic DNA. Genomic DNA was
isolated from a single individual fish by a standard method
(Sambrook et al., 1989). Generally, an adult fish was quickly
frozen in liquid nitrogen and ground into powder. The ground tissue
was then transferred to an extraction buffer (10 mM Tris, pH 8, 0.1
M EDTA, 20 .mu.g/ml RNase A and 0.5% SDS) and incubated at
37.degree. C. for 1 hour. Proteinase K was added to a final
concentration of 100 .mu.g/ml and gently mixed until the mixture
appeared viscous, followed by incubation at 50.degree. C. for 3
hours with periodical swirling. The genomic DNA was gently
extracted three times by phenol equilibrated with Tris-HCl (pH 8),
precipitated by adding 0.1 volume of 3 M NaOAc and 2.5 volumes of
ethanol, and collected by swirling on a glass rod, then rinsed in
70% ethanol.
[0074] 3. Digestion of genomic DNA by a restriction enzyme. Genomic
DNA was digested with the selected restriction enzymes. Generally,
500 units of restriction enzyme were used to digest 50 .mu.g of
genomic DNA overnight at the optimal enzyme reaction temperature
(usually at 37.degree. C.).
[0075] 4. Ligation of a short linker DNA to the digested genomic
DNA. The linker DNA was assembled by annealing equal moles of the
two linker oligonucleotides, Oligo1 (SEQ ID NO:16) and Oligo 2 (SEQ
ID NO:17). Oligo 2 was phosphorylated by T4 polynucleotide kinase
prior to annealing. Restriction enzyme digested genomic DNA was
filled-in or trimmed with T4 DNA polymerase, if necessary, and
ligated with the linker DNA. Ligation was performed with 1 .mu.g of
digested genomic DNA and 0.5 .mu.g of linker DNA in a 20 .mu.l
reaction containing 10 units of T4 DNA ligase at 4.degree. C.
overnight.
[0076] 5. PCR amplification of promoter region. PCR was performed
with Advantage Tth Polymerase Mix (Clontech). The first round of
PCR was performed using a linker specific primer L1 (SEQ ID NO:18)
and a gene specific primer G1 (CK1, MCK1, M1 or ARP1). Each
reaction (50 .mu.l) contains 5 .mu.l of 10.times.Tth PCR reaction
buffer (1X=15 mM KOAc, 40 mM Tris, pH 9.3), 2.2 .mu.l of 25 mM
Mg(OAc)2, 5 .mu.l of 2 mM dNTP, 1 .mu.l of L1 (0.2 .mu.g/.mu.l), 1
.mu.l of G1 (0.2 .mu.g/.mu.l), 33.8 .mu.l of H2O, and 1 .mu.l (50
ng) of linker ligated genomic DNA and 1 .mu.l of 50.times. Tth
polymerase mix (Clontech). The cycling conditions were as follows:
94.degree. C./1 min, 35 cycles of 94.degree. C./30 sec and
68.degree. C./6 min, and finally 68.degree. C./8 min. After the
primary round of PCR was completed, the products were diluted 100
fold. One .mu.l of diluted PCR product was used as template for the
second round of PCR (nested PCR) with a second linker specific
primer L2 (SEQ ID NO:19) and a second gene specific primer G2 (CK2,
MCK2, M2 or ARP2), as described for the primary PCR but with the
following modification: 94.degree. C./1 min, 25 cycles of
94.degree. C./30 sec and 68.degree. C./6 min, and finally
68.degree. C./8 min. Both the primary and secondary PCR products
were analyzed on a 1% agarose gel.
[0077] 6. DNA sequencing to confirm the cloned DNA fragment. PCR
products were purified from the agarose gel following
electrophoresis and cloned into a TA vector, pT7Blue.TM. (Novogen).
DNA sequencing was performed by dideoxynucleotide chain termination
method using a T7 Sequencing Kit purchased from Pharmacia. Complete
sequences of these promoter regions were obtained by automatic
sequencing using a dRhodamine Terminator Cycle Sequencing Ready
Reaction Kit (Perkin-Elmer) and an ABI 377 automatic sequencing
machine.
[0078] The isolated cytokeratin DNA fragment comprising the gene
promoter is 2.2 kb. In the 3' proximal region immediately upstream
of a portion identical to the 3' part of the CK cDNA sequence,
there is a putative TATA box perfectly matching to a consensus TATA
box sequence. The 164 bp of the 3' region is identical to the 5'
UTR (untranslated region) of the cytokeratin cDNA. Thus, the
isolated fragment was indeed derived from the same gene as the
cytokeratin cDNA clone (SEQ ID NO:7). Similarly, a 1.5 kb 5'
flanking region was isolated from the muscle creatine kinase gene,
a putative TATA box was also found in its 3' proximal region and
the 3' region is identical to the 5' portion of the MCK cDNA clone
(SEQ ID NO:8). For MLC2f, a 2 kb region was isolated from the fast
skeletal muscle isoform of myosin light chain 2 gene and sequenced
completely. The promoter sequence for MLC2f is shown in SEQ ID
NO:22. The sequence immediately upstream of the gene specific
primer M2 is identical to the 5' UTR of the MLC2f cDNA clone; thus,
the amplified DNA fragments are indeed derived from the MLC2f gene.
A perfect TATA box was found 30 nucleotides upstream of the
transcription start site, which was defined by a primer extension
experiment based on Sambrook et al. (1989). In the 2-kb region
comprising the promoter, six E-boxes (CANNTG) and six potential
MEF2 binding sites [C/T) TA(T/A)4TA(A/G)] were found and are
indicated in SEQ ID NO:22. Both of these cis-element classes are
important for muscle specific gene transcription (Schwarz et al.,
1993; Olson et al., 1995). A 2.2 kb fragment was amplified for the
ARP gene. By alignment of its sequence with the ARP cDNA clone, a
1.3 kb intron was found in the 5' UTR (SEQ ID NO:9). As a result,
the isolated ARP promoter is within a DNA fragment about 0.8 kb
long.
[0079] Example III: Generation of green fluorescent transgenic fish
The isolated zebrafish gene promoters were inserted into the
plasmid pEGFP-1 (Clonetech), which contains an EGFP structural gene
whose codons have been optimized according to preferable human
codons. Three promoter fragments were inserted into pEGFP-1 at the
EcoRI and BamHI site and the resulting recombinant plasmids were
named pCK-EGFP (FIG. 4), pMCK-EGFP (FIG. 5), and pARP-EGFP,
respectively (FIG. 6). The promoter fragment for the MLC2f gene was
inserted into the Hind III and Bam HI sites of the plasmid pEGFP-1
and the resulting chimeric DNA construct, pMLC2f-EGFP, is diagramed
in FIG. 7.
[0080] Linearized plasmid DNAs at a concentrations of 500 .mu.g/ml
(for pCK-EGFP and pMCK-EGFP) and 100 .mu.g/ml (for pMLC2f-EGFP) in
0.1 M Tris-HCl (pH 7.6)/0.25% phenol red were injected into the
cytoplasm of 1- or 2-cell stage embryos. Because of a high
mortality rate, pARP-EGFP was injected at a lower concentration (50
.mu.g/ml). Each embryo received 300-500 pl of DNA. The injected
embryos were reared in autoclaved Holtfreter"s solution (0.35%
NaCl, 0.01% KCl and 0.01% CaCl2) supplemented with 1 .mu.g/ml of
methylene blue. Expression of GFP was observed and photographed
under a ZEISS Axiovert 25 fluorescence microscope.
[0081] When zebrafish embryos received pCK-EGFP, GFP expression
started about 4 hours after injection, which corresponds to the
stage of .about.30% epiboly. About 55% of the injected embryos
expressed GFP at this stage. The early expression was always in the
superficial layer of cells, mimicking endogenous expression of the
CK gene as observed by in situ hybridization. At later stages, in
all GFP-expressing fish, GFP was found predominantly in skin
epithelia. A typical pCK-EGFP transgenic zebrafish fry at 4 days
old is shown in FIG. 8.
[0082] Under the MCK promoter, no GFP expression was observed in
early embryos before muscle cells become differentiated. By 24 hpf,
about 12% of surviving embryos expressed GFP strongly in muscle
cells and these GFP-positive embryos remain GFP-positive after
hatching. The GFP expression was always found in many bundles of
muscle fibers, mainly in the mid-trunk region and no expression was
ever found in other types of cells. A typical pMCK-EGFP transgenic
zebrafish fry (3 days old) is shown in FIG. 9.
[0083] Expression of pARP-EGFP was first observed 4 hours after
injection at the 30% epiboly stage. The timing of expression is
similar to that of pCK-EGFP-injected embryos. However, unlike the
pCK-EGFP transgenic embryos, the GFP expression under the ARP
promoter occurred not only in the superficial layer of cells but
also in deep layers of cells. In some batches of injected embryos,
almost 100% of the injected embryos expressed initially. At later
stages when some embryonic cells become overtly differentiated, it
was found that the GFP expression occurred essentially in all
different types of cells such as skin epithelia, muscle cells,
lens, neural tissues, notochord, circulating blood cells and yolk
cells (FIG. 10).
[0084] Under the MLC2f promoter, nearly 60% of the embryos
expressed GFP. The earliest GFP expression started in trunk
skeletal muscles about 19 hours after injection, which corresponds
to the stage of 20-somite. Later, the GFP expression also occurred
in head skeletal muscles including eye muscles, jaw muscles, gill
muscles etc.
[0085] Transgenic founder zebrafish containing pMLC2f-EGFP emit a
strong green fluorescent light under a blue or ultraviolet light
(FIG. 11A). When the transgenic founders were crossed with
wild-type fish, transgenic offspring were obtained that also
displayed strong green fluorescence (FIG. 11B). The level of GFP
expression is so high in the transgenic founders and offspring that
green fluorescence can be observed when the fish are exposed to
sunlight.
[0086] To identify the DNA elements conferring the strong promoter
activity in skeletal muscles, deletion analysis of the 2-kb DNA
fragment comprising the promoter was performed. Several deletion
constructs, which contain 5'' deletions of the MLC2f promoter
upstream of the EGFP gene, were injected into the zebrafish embryos
and the transient expression of GFP in early embryos (19-72 hpf)
was compared. To facilitate the quantitative analysis of GFP
expression, we define the level of expression as follows (FIGS.
12A-12C): Strong expression: GFP expression was detected in
essentially 100% muscle fibers in the trunk.
[0087] Moderate expression: GFP expression was detected in several
bundles of muscle fibers, usually in the mid-trunk region.
[0088] Weak expression: GFP expression occurred in dispersed muscle
fibers and the number of GFP positive fibers is usually less than
20 per embryo.
[0089] As shown in FIG. 13, deletion up to 283 bp maintained the
GFP expression in skeletal muscles in 100% of the expressing
embryos; however, the level of GFP expression from these deletion
constructs varies greatly. Strong expression drops from 23% to 0%
from the 2-kb (-2011 bp) promoter to the 283-bp promoter. Thus,
only two constructs (2011 bp and 1338 bp) are capable of
maintaining the high level of expression and the highest expression
was obtained only with the 2-kb promoter, indicating the importance
of the promoter region of 1338 bp to 2011 bp for conferring the
highest promoter activity.
[0090] The expression of GFP using pMLC2f-EGFP is much higher than
that obtained using the pMCK-EGFP that contains a 1.5 kb of
zebrafish MCK promoter (Singapore Patent Application 9900811-2). By
the same assay in transient transgenic zebrafish embryos, only
about 12% of the embryos injected with pMCK-EGFP expressed GFP.
Among the expressing embryos, no strong expression was observed,
and 70% and 30% showed moderate and weak expression, respectively.
In comparison, about 60% of the embryos injected with pMLC2f-EGFP
expressed GFP and 23%, 37% and 40% showed strong, moderate and weak
expression, respectively.
[0091] Example IV: Potential applications of fluorescent transgenic
fish The fluorescent transgenic fish have use as ornamental fish in
the market. Stably transgenic lines can be developed by breeding a
GFP transgenic individual with a wild type fish or another
transgenic fish. By isolation of more zebrafish gene promoters,
such as eye-specific, bone-specific, tail-specific etc., and/or by
classical breeding of these transgenic zebrafish, more varieties of
fluorescent transgenic zebrafish can be produced. Previously, we
have reported isolation of over 200 distinct zebrafish cDNA clones
homologous to known genes (Gong et al., 1997). These isolated
clones code for proteins in a variety of tissues and some of them
are inducible by heat-shock, heavy metals, or hormones such as
estrogens. By using the method of PCR amplification using
gene-specific primers designed from the nucleotide sequences of
these cDNAs, and the linker-specific primers described herein, the
promoters of the genes represented by the cDNAs of Gong et al. can
be used in the present invention. Thus, hormone-inducible
promoters, heavy-metal inducible promoters and the like from
zebrafish can be isolated and used to make fluorescent zebrafish
(or other fish species) that express a GFP or variant thereof, in
response to the relevant compound.
[0092] Multiple color fluorescent fish may be generated by the same
technique as blue fluorescent protein (BFP) gene, yellow
fluorescent protein (YFP) gene and cyan fluorescent protein (CFP)
gene are available from Clonetech. For example, a transgenic fish
with GFP under an eye-specific promoter, BFP under a skin-specific
promoter, and YFP under a muscle-specific promoter will show the
following multiple fluorescent colors: green eyes, blue skin and
yellow muscle. By recombining different tissue specific promoters
and fluorescent protein genes, more varieties of transgenic fish of
different fluorescent color patterns will be created. By expression
of two or more different fluorescent proteins in the same tissue,
an intermediate color may be created. For example, expression of
both GFP and BFP under a skin-specific promoter, a dark-green skin
color may be created.
[0093] By using a heavy metal--(such as cadmium, cobalt, chromium)
inducible or hormone--(such as estrogen, androgen or other steroid
hormone) inducible promoter, a biosensor system may be developed
for monitoring environmental pollution and for evaluating water
quality for human consumption and aquacultural uses. In such a
biosensor system, the transgenic fish will glow with a green
fluorescence (or other color depending on the fluorescence protein
gene used) when pollutants such as heavy metals and estrogens (or
their derivatives) reach a threshold concentration in an aquatic
environment. Such a biosensor system has advantages over classical
analytical methods because it is rapid, visualizable, and capable
of identifying specific compounds directly in complex mixture found
in an aquatic environment, and is portable or less instrument
dependent. Moreover, the biosensor system also provides direct
information on biotoxicity and it is biodegradable and
regenerative.
[0094] Environmental monitoring of several substances can be
accomplished by either creating one transgenic fish having genes
encoding different colored fluorescent proteins driven by promoters
responsive to each substance. Then the particular colors exhibited
the fish in an environment can be observed. Alternatively, a number
of fish can be transformed with individual vectors, then the fish
can be combined into a population for monitoring an environment and
the colors expressed by each fish observed.
[0095] In addition, the fluorescent transgenic fish should also be
valuable in the market for scientific research tools because they
can be used for embryonic studies such as tracing cell lineage and
cell migration. Cells from transgenic fish expressing GFP can also
be used as cellular and genetic markers in cell transplantation and
nuclear transplantation experiments.
[0096] The chimeric gene constructs demonstrated successfully in
zebrafish in the present invention should also be applicable to
other fish species such as medaka, goldfish, carp including koi,
loach, tilapia, glassfish, catfish, angel fish, discus, eel, tetra,
goby, gourami, guppy, Xiphophorus (swordtail), hatchet fish, Molly
fish, Pangasius, etc. The promoters described herein can be used
directly in these fish species. Alternatively, the homologous gene
promoters from other fish species can be isolated by the method
described in this invention. For example, the isolated and
characterized zebrafish cDNA clones and promoters described in this
invention can be used as molecular probes to screen for homologous
promoters in other fish species by molecular hybridization or by
PCR. Alternatively, one can first isolate the zebrafish cDNA and
promoters based on the sequences presented in SEQ ID NOS:1, 3, 5,
7, 8, 9, 20 and 22 or using data from other sequences of cDNAs
disclosed by Gong et al. 1997, by PCR and then use the zebrafish
gene fragments to obtain homologous genes from other fish species
by the methods mentioned above.
[0097] In addition, a strong muscle-specific promoter such as MLC2f
is valuable to direct a gene to be expressed in muscle tissues for
generation of other beneficial transgenic fish. For example,
transgenic expression of a growth hormone gene under the
muscle-specific promoter may stimulate somatic growth of transgenic
fish. Such DNA can be introduced either by microinjection,
electroporation, or sperm carrier to generate germ-line transgenic
fish, or by direct injection of naked DNA into skeletal muscles (Xu
et al., 1999) or into other tissues or cavities, or by a biolistic
method (gene bombardment or gene gun) (Gomez-Chiarri et al., 1996).
Sequence CWU 1
1
2412480DNADanio rerioprimer bind(66)..(85)CK2CDS(90)..(1586)primer
bind(97)..(120)CK1polyA signal(2463)..(2480) 1ctctcctttg tgagcaacct
cctccactca ctcctctctc agagagcact ctcgtacctc 60cttctcagca actcaaagac
acaggcatc atg tca acc agg tct atc tct tac 113 Met Ser Thr Arg Ser
Ile Ser Tyr 1 5tcc agc ggt ggc tcc atc agg agg ggc tac acc agc cag
tca gcc tat 161Ser Ser Gly Gly Ser Ile Arg Arg Gly Tyr Thr Ser Gln
Ser Ala Tyr 10 15 20gca gta cct gcc ggc tct acc agg atg agc tca gtg
acc agt gtc agg 209Ala Val Pro Ala Gly Ser Thr Arg Met Ser Ser Val
Thr Ser Val Arg25 30 35 40aga tct ggt gtg ggt gcc agc cca ggc ttc
ggt gcc ggt ggc agc tac 257Arg Ser Gly Val Gly Ala Ser Pro Gly Phe
Gly Ala Gly Gly Ser Tyr 45 50 55agc ttt agc agc agc agc atg ggt gga
ggc tat gga agt ggt ctt ggt 305Ser Phe Ser Ser Ser Ser Met Gly Gly
Gly Tyr Gly Ser Gly Leu Gly 60 65 70gga ggt ctc ggt ggg ggc atg ggc
ttt cgt tgc ggg ctt cct atc aca 353Gly Gly Leu Gly Gly Gly Met Gly
Phe Arg Cys Gly Leu Pro Ile Thr 75 80 85gct gta act gtc aac cag aac
ctg ttg gcc ccc tta aac ctg gaa atc 401Ala Val Thr Val Asn Gln Asn
Leu Leu Ala Pro Leu Asn Leu Glu Ile 90 95 100gac ccc aca att caa
gct gtc cgc act tca gag aaa gag cag att aag 449Asp Pro Thr Ile Gln
Ala Val Arg Thr Ser Glu Lys Glu Gln Ile Lys105 110 115 120acc ttc
aac aac cgc ttc gct ttc ctc atc gac aaa gtg cgc ttc ctg 497Thr Phe
Asn Asn Arg Phe Ala Phe Leu Ile Asp Lys Val Arg Phe Leu 125 130
135gaa cag cag aac aag atg ctt gag acc aaa tgg agt ctt ctc caa gaa
545Glu Gln Gln Asn Lys Met Leu Glu Thr Lys Trp Ser Leu Leu Gln Glu
140 145 150cag aca acc aca cgt tcc aac atc gat gcc atg ttt gag gca
tac atc 593Gln Thr Thr Thr Arg Ser Asn Ile Asp Ala Met Phe Glu Ala
Tyr Ile 155 160 165tct aac ctg cgc aga cag ctc gat gga ctg gga aat
gag aag atg aag 641Ser Asn Leu Arg Arg Gln Leu Asp Gly Leu Gly Asn
Glu Lys Met Lys 170 175 180ctg gag gga gag ctg aag aac atg cag ggc
ctg gtt gag gac ttc aag 689Leu Glu Gly Glu Leu Lys Asn Met Gln Gly
Leu Val Glu Asp Phe Lys185 190 195 200aac aag tac gag gat gag atc
aac aag cgt gct tcc gta gag aat gag 737Asn Lys Tyr Glu Asp Glu Ile
Asn Lys Arg Ala Ser Val Glu Asn Glu 205 210 215ttt gtc ctg ctc aag
aag gat gtt gat gca gcc tac atg aac aag gtt 785Phe Val Leu Leu Lys
Lys Asp Val Asp Ala Ala Tyr Met Asn Lys Val 220 225 230gag ctt gaa
gcc aag gtt gat gct ctt cag gat gag atc aac ttc ctc 833Glu Leu Glu
Ala Lys Val Asp Ala Leu Gln Asp Glu Ile Asn Phe Leu 235 240 245agg
gca gtc tac gag gct gaa ctc cgg gag ctc cag tct cag atc aag 881Arg
Ala Val Tyr Glu Ala Glu Leu Arg Glu Leu Gln Ser Gln Ile Lys 250 255
260gac aca tct gtt gtt gta gaa atg gac aac agc aga aac ctg gat atg
929Asp Thr Ser Val Val Val Glu Met Asp Asn Ser Arg Asn Leu Asp
Met265 270 275 280gac tcc atc gtg gct gaa gtt cgc gct cag tat gaa
gac atc gcc aac 977Asp Ser Ile Val Ala Glu Val Arg Ala Gln Tyr Glu
Asp Ile Ala Asn 285 290 295cgc agc cgt gcc gag gca gag agc tgg tac
aaa cag aag ttt gag gag 1025Arg Ser Arg Ala Glu Ala Glu Ser Trp Tyr
Lys Gln Lys Phe Glu Glu 300 305 310atg cag agc acc gct ggt cag tat
ggt gat gac ctc cgc tca aca aag 1073Met Gln Ser Thr Ala Gly Gln Tyr
Gly Asp Asp Leu Arg Ser Thr Lys 315 320 325gct gag att gct gaa ctc
aac cgc atg atc gcc cgc ctg cag aac gag 1121Ala Glu Ile Ala Glu Leu
Asn Arg Met Ile Ala Arg Leu Gln Asn Glu 330 335 340atc gat gct gtc
aag gca cag cgt gcc aac ttg gag gct cag att gct 1169Ile Asp Ala Val
Lys Ala Gln Arg Ala Asn Leu Glu Ala Gln Ile Ala345 350 355 360gag
gct gaa gag cgt gga gag ctg gca gtg aag gat gcc aag ctc cgc 1217Glu
Ala Glu Glu Arg Gly Glu Leu Ala Val Lys Asp Ala Lys Leu Arg 365 370
375atc agg gag ctg gag gaa gct ctt cag agg gcc aag caa gac atg gcc
1265Ile Arg Glu Leu Glu Glu Ala Leu Gln Arg Ala Lys Gln Asp Met Ala
380 385 390cgc cag gtc cgc gag tac cag gag ctc atg aac gtc aaa ttg
gct ctg 1313Arg Gln Val Arg Glu Tyr Gln Glu Leu Met Asn Val Lys Leu
Ala Leu 395 400 405gac att gag atc gcc acc tac agg aaa ctg ttg gaa
gga gag gag agc 1361Asp Ile Glu Ile Ala Thr Tyr Arg Lys Leu Leu Glu
Gly Glu Glu Ser 410 415 420aga ctg tcc agc ggt gga gct caa gct acc
att cat gtt cag cag acc 1409Arg Leu Ser Ser Gly Gly Ala Gln Ala Thr
Ile His Val Gln Gln Thr425 430 435 440tcc gga ggt gtt tca tct ggt
tat ggt ggt agc ggc tct ggt ttc ggc 1457Ser Gly Gly Val Ser Ser Gly
Tyr Gly Gly Ser Gly Ser Gly Phe Gly 445 450 455tac agc agt ggc ttc
agc agt ggt ggg tca gga tac ggt agt gga tca 1505Tyr Ser Ser Gly Phe
Ser Ser Gly Gly Ser Gly Tyr Gly Ser Gly Ser 460 465 470gga ttc ggt
tct gga tca ggg tat ggt gga ggc tcc atc agc aaa acc 1553Gly Phe Gly
Ser Gly Ser Gly Tyr Gly Gly Gly Ser Ile Ser Lys Thr 475 480 485agt
gtc acc acc gtc agc agt aaa cgc tat taa ggagaagccc gcccaaaccc
1606Ser Val Thr Thr Val Ser Ser Lys Arg Tyr 490 495ccagccgaca
cagtttccaa ccttccttac ctgcaactag atcccttctg aaccttctta
1666cgactcaaac catctatggt gctatatttt agccagacag ctgtcccctg
ttaatgagga 1726gatgtggacg atgattttta aagtacaaaa taagttttag
attgttctgt gtgttgatgg 1786tagttacccg tatcatgcat ctcctgtctg
gtggtgtcac tgccatttta aatcatcaac 1846ccaactacac taaaacgata
ccaggaagaa tcgtgctcca agccactgaa tagtcttatt 1906tctgcactga
tatgtacagg gaaagtgaga cacatagaaa ccactgtaac ctacgtagta
1966ctatggtttc actggatcag gggtgtgcta tacaagttcc tgaatgtctt
gtttgaatgt 2026tttgtgctgt tacaagctcc ctgctgtagt tttgctgact
aatctgactt ttgtcatttt 2086gctatggctg tcagagttgg tttacctatt
ttctataaaa tgtatatggc agtcagccaa 2146taactgatga caattgcttg
tgggctacta atgtccagtt acctcacatt caagggagat 2206ctgttacagc
aaaaaacagg cacaatggga tttatgtgga ccatccctcc ttaaccttgt
2266gtactttccg tgttggaagt ggtgactgta ctgccttaca cattcccctg
tattcaactg 2326gcttccagag catattttac atccccggtt ataaatggaa
aatgcaagaa aactgaaaca 2386atgttcaacc agatttattt ggtattgatt
gacgagacac caacttgaaa tttgaataca 2446ataaatctga gaccacaaaa
aaaaaaaaaa aaaa 24802498PRTDanio rerio 2Met Ser Thr Arg Ser Ile Ser
Tyr Ser Ser Gly Gly Ser Ile Arg Arg1 5 10 15Gly Tyr Thr Ser Gln Ser
Ala Tyr Ala Val Pro Ala Gly Ser Thr Arg 20 25 30Met Ser Ser Val Thr
Ser Val Arg Arg Ser Gly Val Gly Ala Ser Pro 35 40 45Gly Phe Gly Ala
Gly Gly Ser Tyr Ser Phe Ser Ser Ser Ser Met Gly 50 55 60Gly Gly Tyr
Gly Ser Gly Leu Gly Gly Gly Leu Gly Gly Gly Met Gly65 70 75 80Phe
Arg Cys Gly Leu Pro Ile Thr Ala Val Thr Val Asn Gln Asn Leu 85 90
95Leu Ala Pro Leu Asn Leu Glu Ile Asp Pro Thr Ile Gln Ala Val Arg
100 105 110Thr Ser Glu Lys Glu Gln Ile Lys Thr Phe Asn Asn Arg Phe
Ala Phe 115 120 125Leu Ile Asp Lys Val Arg Phe Leu Glu Gln Gln Asn
Lys Met Leu Glu 130 135 140Thr Lys Trp Ser Leu Leu Gln Glu Gln Thr
Thr Thr Arg Ser Asn Ile145 150 155 160Asp Ala Met Phe Glu Ala Tyr
Ile Ser Asn Leu Arg Arg Gln Leu Asp 165 170 175Gly Leu Gly Asn Glu
Lys Met Lys Leu Glu Gly Glu Leu Lys Asn Met 180 185 190Gln Gly Leu
Val Glu Asp Phe Lys Asn Lys Tyr Glu Asp Glu Ile Asn 195 200 205Lys
Arg Ala Ser Val Glu Asn Glu Phe Val Leu Leu Lys Lys Asp Val 210 215
220Asp Ala Ala Tyr Met Asn Lys Val Glu Leu Glu Ala Lys Val Asp
Ala225 230 235 240Leu Gln Asp Glu Ile Asn Phe Leu Arg Ala Val Tyr
Glu Ala Glu Leu 245 250 255Arg Glu Leu Gln Ser Gln Ile Lys Asp Thr
Ser Val Val Val Glu Met 260 265 270Asp Asn Ser Arg Asn Leu Asp Met
Asp Ser Ile Val Ala Glu Val Arg 275 280 285Ala Gln Tyr Glu Asp Ile
Ala Asn Arg Ser Arg Ala Glu Ala Glu Ser 290 295 300Trp Tyr Lys Gln
Lys Phe Glu Glu Met Gln Ser Thr Ala Gly Gln Tyr305 310 315 320Gly
Asp Asp Leu Arg Ser Thr Lys Ala Glu Ile Ala Glu Leu Asn Arg 325 330
335Met Ile Ala Arg Leu Gln Asn Glu Ile Asp Ala Val Lys Ala Gln Arg
340 345 350Ala Asn Leu Glu Ala Gln Ile Ala Glu Ala Glu Glu Arg Gly
Glu Leu 355 360 365Ala Val Lys Asp Ala Lys Leu Arg Ile Arg Glu Leu
Glu Glu Ala Leu 370 375 380Gln Arg Ala Lys Gln Asp Met Ala Arg Gln
Val Arg Glu Tyr Gln Glu385 390 395 400Leu Met Asn Val Lys Leu Ala
Leu Asp Ile Glu Ile Ala Thr Tyr Arg 405 410 415Lys Leu Leu Glu Gly
Glu Glu Ser Arg Leu Ser Ser Gly Gly Ala Gln 420 425 430Ala Thr Ile
His Val Gln Gln Thr Ser Gly Gly Val Ser Ser Gly Tyr 435 440 445Gly
Gly Ser Gly Ser Gly Phe Gly Tyr Ser Ser Gly Phe Ser Ser Gly 450 455
460Gly Ser Gly Tyr Gly Ser Gly Ser Gly Phe Gly Ser Gly Ser Gly
Tyr465 470 475 480Gly Gly Gly Ser Ile Ser Lys Thr Ser Val Thr Thr
Val Ser Ser Lys 485 490 495Arg Tyr31589DNADanio rerioprimer
bind(6)..(26)MCK2primer bind(20)..(38)MCK1CDS(86)..(1231)polyA
signal(1534)..(1539) 3cctatttcgg cttggtgaac aggatctgat cccaaggact
gttaccactt ttgttgtctt 60ttgtgcagtg ttagaaaccg caatc atg cct ttc gga
aac acc cac aac aac 112 Met Pro Phe Gly Asn Thr His Asn Asn 1 5ttc
aag ctg aac tac tca gtt gat gag gag tat cca gac ctt agc aag 160Phe
Lys Leu Asn Tyr Ser Val Asp Glu Glu Tyr Pro Asp Leu Ser Lys10 15 20
25cac aac aac cac atg gcc aag gtg ctg act aag gaa atg tat ggc aag
208His Asn Asn His Met Ala Lys Val Leu Thr Lys Glu Met Tyr Gly Lys
30 35 40ctt agg gac aag cag acc cca cct gga ttc act gtg gat gat gtc
atc 256Leu Arg Asp Lys Gln Thr Pro Pro Gly Phe Thr Val Asp Asp Val
Ile 45 50 55cag act ggt gtt gac aat cca ggc cac ccc ttc atc atg acc
gtc ggc 304Gln Thr Gly Val Asp Asn Pro Gly His Pro Phe Ile Met Thr
Val Gly 60 65 70tgt gtt gct ggt gat gag gag tcc tac gat gtt ttc aag
gac ctg ttc 352Cys Val Ala Gly Asp Glu Glu Ser Tyr Asp Val Phe Lys
Asp Leu Phe 75 80 85gac ccc gtc att tcc gac cgt cac ggt gga tac aag
gca act gac aag 400Asp Pro Val Ile Ser Asp Arg His Gly Gly Tyr Lys
Ala Thr Asp Lys90 95 100 105cac aag acc gac ctc aac ttt gag aac ctg
aag ggt ggt gat gac ctg 448His Lys Thr Asp Leu Asn Phe Glu Asn Leu
Lys Gly Gly Asp Asp Leu 110 115 120gac ccc aac tac ttc ctg agc agc
cgt gtg cgt acc gga cgc agc atc 496Asp Pro Asn Tyr Phe Leu Ser Ser
Arg Val Arg Thr Gly Arg Ser Ile 125 130 135aag gga tac ccc ctg ccc
ccc cac aac agc cgt gga gag cgc aga gct 544Lys Gly Tyr Pro Leu Pro
Pro His Asn Ser Arg Gly Glu Arg Arg Ala 140 145 150gtg gag aag ctg
tct gtt gaa gct ctg agt agc ttg gat gga gag ttc 592Val Glu Lys Leu
Ser Val Glu Ala Leu Ser Ser Leu Asp Gly Glu Phe 155 160 165aag ggc
aag tac tac ccc ctg aag tcc atg act gat gac gag cag gag 640Lys Gly
Lys Tyr Tyr Pro Leu Lys Ser Met Thr Asp Asp Glu Gln Glu170 175 180
185cag ctg atc gct gac cac ttc ctc ttt gac aaa ccc gtc tcc ccc ctg
688Gln Leu Ile Ala Asp His Phe Leu Phe Asp Lys Pro Val Ser Pro Leu
190 195 200ctg ctg gct gct ggt atg gcc cgt gac tgg ccc gat gcc aga
ggc att 736Leu Leu Ala Ala Gly Met Ala Arg Asp Trp Pro Asp Ala Arg
Gly Ile 205 210 215tgg cac aat gag aac aaa gcc ttc ctg gtc tgg gtg
aaa cag gag gat 784Trp His Asn Glu Asn Lys Ala Phe Leu Val Trp Val
Lys Gln Glu Asp 220 225 230cac ctg cgt gtc att tcc atg cag aag ggt
ggc aac atg aag gaa gtg 832His Leu Arg Val Ile Ser Met Gln Lys Gly
Gly Asn Met Lys Glu Val 235 240 245ttc aag cgc ttc tgc gtt ggt ctt
cag agg att gag gaa att ttc aag 880Phe Lys Arg Phe Cys Val Gly Leu
Gln Arg Ile Glu Glu Ile Phe Lys250 255 260 265aag cac aac cat ggg
ttc atg tgg aac gag cat ctt ggt ttc gtc ctg 928Lys His Asn His Gly
Phe Met Trp Asn Glu His Leu Gly Phe Val Leu 270 275 280acc tgc ccc
tcc aac ctg ggc aca ggc ctg cgc ggt gga gtc cac gtc 976Thr Cys Pro
Ser Asn Leu Gly Thr Gly Leu Arg Gly Gly Val His Val 285 290 295aag
ctg ccc aag ctc agc aca cat gcc aag ttt gag gag atc ctg acc 1024Lys
Leu Pro Lys Leu Ser Thr His Ala Lys Phe Glu Glu Ile Leu Thr 300 305
310aga ctg cgc ctg cag aag cgt ggc aca ggg ggt gtg gac acc gct tcc
1072Arg Leu Arg Leu Gln Lys Arg Gly Thr Gly Gly Val Asp Thr Ala Ser
315 320 325gtt ggt gga gtg ttt gac att tcc aac gct gac cgt atc ggc
tct tca 1120Val Gly Gly Val Phe Asp Ile Ser Asn Ala Asp Arg Ile Gly
Ser Ser330 335 340 345gag gtt gag cag gtg cag tgt gtg gtt gat ggt
gtc aag ctg atg gtg 1168Glu Val Glu Gln Val Gln Cys Val Val Asp Gly
Val Lys Leu Met Val 350 355 360gag atg gag aag aag ctg gga gaa ggc
cag tcc atc gac agc atg atc 1216Glu Met Glu Lys Lys Leu Gly Glu Gly
Gln Ser Ile Asp Ser Met Ile 365 370 375cct gcc cag aag taa
agcgggaggc ccttccattt ttttcttcgt ctttgtctgt 1271Pro Ala Gln Lys
380ttttttacag tccaacagca acgsagagga aaactgctgc tcaaaaagac
agtctcacct 1331ttgcacctgt cttctttcct ttttttccct tcttctctaa
tttccatgtc atttcgccat 1391ctttttttcc actttgtttc ctattaagtc
ggtaacatct tgggatcaga tacccggsgc 1451aggagtgagt gcttgttgct
gaggcttcac ctcaatttca gccttggttg taaaaagtga 1511atcaatcaaa
gttgtatttc aaaataaaaa tccccaataa aaaaaaaaaa aaaaaaaaaa
1571aaaaaaaaaa aaaaaaaa 15894381PRTDanio rerio 4Met Pro Phe Gly Asn
Thr His Asn Asn Phe Lys Leu Asn Tyr Ser Val1 5 10 15Asp Glu Glu Tyr
Pro Asp Leu Ser Lys His Asn Asn His Met Ala Lys 20 25 30Val Leu Thr
Lys Glu Met Tyr Gly Lys Leu Arg Asp Lys Gln Thr Pro 35 40 45Pro Gly
Phe Thr Val Asp Asp Val Ile Gln Thr Gly Val Asp Asn Pro 50 55 60Gly
His Pro Phe Ile Met Thr Val Gly Cys Val Ala Gly Asp Glu Glu65 70 75
80Ser Tyr Asp Val Phe Lys Asp Leu Phe Asp Pro Val Ile Ser Asp Arg
85 90 95His Gly Gly Tyr Lys Ala Thr Asp Lys His Lys Thr Asp Leu Asn
Phe 100 105 110Glu Asn Leu Lys Gly Gly Asp Asp Leu Asp Pro Asn Tyr
Phe Leu Ser 115 120 125Ser Arg Val Arg Thr Gly Arg Ser Ile Lys Gly
Tyr Pro Leu Pro Pro 130 135 140His Asn Ser Arg Gly Glu Arg Arg Ala
Val Glu Lys Leu Ser Val Glu145 150 155 160Ala Leu Ser Ser Leu Asp
Gly Glu Phe Lys Gly Lys Tyr Tyr Pro Leu 165 170 175Lys Ser Met Thr
Asp Asp Glu Gln Glu Gln Leu Ile Ala Asp His Phe 180 185 190Leu Phe
Asp Lys Pro Val Ser Pro Leu Leu Leu Ala Ala Gly Met Ala 195 200
205Arg Asp Trp Pro Asp Ala Arg Gly Ile Trp His Asn Glu Asn Lys Ala
210 215 220Phe Leu Val Trp Val Lys Gln Glu Asp His Leu Arg Val Ile
Ser Met225 230 235 240Gln Lys Gly Gly Asn Met Lys Glu Val Phe Lys
Arg Phe Cys Val Gly 245 250 255Leu Gln Arg Ile Glu Glu Ile Phe Lys
Lys His Asn His Gly Phe Met 260
265 270Trp Asn Glu His Leu Gly Phe Val Leu Thr Cys Pro Ser Asn Leu
Gly 275 280 285Thr Gly Leu Arg Gly Gly Val His Val Lys Leu Pro Lys
Leu Ser Thr 290 295 300His Ala Lys Phe Glu Glu Ile Leu Thr Arg Leu
Arg Leu Gln Lys Arg305 310 315 320Gly Thr Gly Gly Val Asp Thr Ala
Ser Val Gly Gly Val Phe Asp Ile 325 330 335Ser Asn Ala Asp Arg Ile
Gly Ser Ser Glu Val Glu Gln Val Gln Cys 340 345 350Val Val Asp Gly
Val Lys Leu Met Val Glu Met Glu Lys Lys Leu Gly 355 360 365Glu Gly
Gln Ser Ile Asp Ser Met Ile Pro Ala Gln Lys 370 375
38051104DNADanio rerioprimer
bind(45)..(64)ARP2CDS(75)..(1034)primer bind(87)..(112)ARKpolyA
signal(1069)..(1074) 5cgcgtcccta ccgtgagatt ttacaacctt gtctttaaac
cggctgttca ccgatccttg 60gaagcactgc aaag atg ccc agg gaa gac agg gcc
acg tgg aag tcc aac 110 Met Pro Arg Glu Asp Arg Ala Thr Trp Lys Ser
Asn 1 5 10tat ttt ctg aaa atc atc caa ctg ctg gat gac ttc ccc aag
tgt ttc 158Tyr Phe Leu Lys Ile Ile Gln Leu Leu Asp Asp Phe Pro Lys
Cys Phe 15 20 25atc gtg ggc gca gac aat gtc ggc tcc aag cag atg cag
acc atc cgt 206Ile Val Gly Ala Asp Asn Val Gly Ser Lys Gln Met Gln
Thr Ile Arg 30 35 40ctg tcc ctg cgg ggc aag gcc gtc gtg ctc atg ggg
aaa aac acc atg 254Leu Ser Leu Arg Gly Lys Ala Val Val Leu Met Gly
Lys Asn Thr Met45 50 55 60atg agg aag gcc att cgt ggc cac ctg gaa
aac aac cca gct ctg gag 302Met Arg Lys Ala Ile Arg Gly His Leu Glu
Asn Asn Pro Ala Leu Glu 65 70 75agg ctg ctt ccc cac atc cgc ggg aac
gtg ggc ttc gtc ttc acc aag 350Arg Leu Leu Pro His Ile Arg Gly Asn
Val Gly Phe Val Phe Thr Lys 80 85 90gag gat ctg act gag gtc cga gac
ctg ctg ctg gca aac aaa gtg ccc 398Glu Asp Leu Thr Glu Val Arg Asp
Leu Leu Leu Ala Asn Lys Val Pro 95 100 105gct gct gcc cgt gct ggt
gcc atc gcc ccc tgt gag gtg act gtg ccg 446Ala Ala Ala Arg Ala Gly
Ala Ile Ala Pro Cys Glu Val Thr Val Pro 110 115 120gcc cag aac acc
ggg ctc ggt cct gag aag acc tct ttc ttc cag gct 494Ala Gln Asn Thr
Gly Leu Gly Pro Glu Lys Thr Ser Phe Phe Gln Ala125 130 135 140ttg
gga atc acc acc aag atc tcc aga gga acc att gaa atc ttg agt 542Leu
Gly Ile Thr Thr Lys Ile Ser Arg Gly Thr Ile Glu Ile Leu Ser 145 150
155gac gtt cag ctt atc aaa cct gga gac aag gtg ggc gcc agc gag gcc
590Asp Val Gln Leu Ile Lys Pro Gly Asp Lys Val Gly Ala Ser Glu Ala
160 165 170acg ctg ctg aac atg ctg aac atg ctg aac atc tcg ccc ttc
tcc tac 638Thr Leu Leu Asn Met Leu Asn Met Leu Asn Ile Ser Pro Phe
Ser Tyr 175 180 185ggg ctg atc atc cag cag gtg tat gat aac ggc agt
gtc tac agc ccc 686Gly Leu Ile Ile Gln Gln Val Tyr Asp Asn Gly Ser
Val Tyr Ser Pro 190 195 200gag gtg ctg gac atc act gag gac gcc ctg
cac aag agg ttc ctg aag 734Glu Val Leu Asp Ile Thr Glu Asp Ala Leu
His Lys Arg Phe Leu Lys205 210 215 220ggt gtg agg aac atc gcc agt
gtg tgt ctg cag atc ggc tac cca act 782Gly Val Arg Asn Ile Ala Ser
Val Cys Leu Gln Ile Gly Tyr Pro Thr 225 230 235ctt gct tcc atc cct
cac act atc atc aat gga tac aag agg gtc ctg 830Leu Ala Ser Ile Pro
His Thr Ile Ile Asn Gly Tyr Lys Arg Val Leu 240 245 250gct gtc act
gtc gaa aca gac tac aca ttc ccc ttg gct gag aag gtg 878Ala Val Thr
Val Glu Thr Asp Tyr Thr Phe Pro Leu Ala Glu Lys Val 255 260 265aag
gcc tac ctg gct gat ccc acc gct ttc gct gtt gca gcc cct gtt 926Lys
Ala Tyr Leu Ala Asp Pro Thr Ala Phe Ala Val Ala Ala Pro Val 270 275
280gcg gca gct aca gag cag aaa tcc gct gct cct gcg gct aaa gag gag
974Ala Ala Ala Thr Glu Gln Lys Ser Ala Ala Pro Ala Ala Lys Glu
Glu285 290 295 300gca ccc aag gag gat tct gag gag tct gat gaa gac
atg ggc ttc ggc 1022Ala Pro Lys Glu Asp Ser Glu Glu Ser Asp Glu Asp
Met Gly Phe Gly 305 310 315ctg ttt gat taa accagacacc gaatatccat
gtctgtttaa catcaataaa 1074Leu Phe Aspacatctggaa aaaaaaaaaa
aaaaaaaaaa 11046319PRTDanio rerio 6Met Pro Arg Glu Asp Arg Ala Thr
Trp Lys Ser Asn Tyr Phe Leu Lys1 5 10 15Ile Ile Gln Leu Leu Asp Asp
Phe Pro Lys Cys Phe Ile Val Gly Ala 20 25 30Asp Asn Val Gly Ser Lys
Gln Met Gln Thr Ile Arg Leu Ser Leu Arg 35 40 45Gly Lys Ala Val Val
Leu Met Gly Lys Asn Thr Met Met Arg Lys Ala 50 55 60Ile Arg Gly His
Leu Glu Asn Asn Pro Ala Leu Glu Arg Leu Leu Pro65 70 75 80His Ile
Arg Gly Asn Val Gly Phe Val Phe Thr Lys Glu Asp Leu Thr 85 90 95Glu
Val Arg Asp Leu Leu Leu Ala Asn Lys Val Pro Ala Ala Ala Arg 100 105
110Ala Gly Ala Ile Ala Pro Cys Glu Val Thr Val Pro Ala Gln Asn Thr
115 120 125Gly Leu Gly Pro Glu Lys Thr Ser Phe Phe Gln Ala Leu Gly
Ile Thr 130 135 140Thr Lys Ile Ser Arg Gly Thr Ile Glu Ile Leu Ser
Asp Val Gln Leu145 150 155 160Ile Lys Pro Gly Asp Lys Val Gly Ala
Ser Glu Ala Thr Leu Leu Asn 165 170 175Met Leu Asn Met Leu Asn Ile
Ser Pro Phe Ser Tyr Gly Leu Ile Ile 180 185 190Gln Gln Val Tyr Asp
Asn Gly Ser Val Tyr Ser Pro Glu Val Leu Asp 195 200 205Ile Thr Glu
Asp Ala Leu His Lys Arg Phe Leu Lys Gly Val Arg Asn 210 215 220Ile
Ala Ser Val Cys Leu Gln Ile Gly Tyr Pro Thr Leu Ala Ser Ile225 230
235 240Pro His Thr Ile Ile Asn Gly Tyr Lys Arg Val Leu Ala Val Thr
Val 245 250 255Glu Thr Asp Tyr Thr Phe Pro Leu Ala Glu Lys Val Lys
Ala Tyr Leu 260 265 270Ala Asp Pro Thr Ala Phe Ala Val Ala Ala Pro
Val Ala Ala Ala Thr 275 280 285Glu Gln Lys Ser Ala Ala Pro Ala Ala
Lys Glu Glu Ala Pro Lys Glu 290 295 300Asp Ser Glu Glu Ser Asp Glu
Asp Met Gly Phe Gly Leu Phe Asp305 310 31572241DNADanio rerioTATA
signal(2103)..(2108)misc feature(2142)..(2235)Identical to the 5'
CK cDNAprimer bind(2221)..(2241)CK2 7ccttcccttc tacttttgac
gtccttttaa gattactcat ctcaaacacc catacaaagg 60tcacacctgg tttatactat
gatagttgta cagtgctggc tgtgacaccc aactgctgcc 120aattgtctga
ctatgcaggg tgtctatgcg tatagtttac agttagacca aagtgtgctg
180gtgtgtgaag taacaaatga caaatactca aattgtaatt tactaagtag
tttaaaaatg 240tagtgcagtg ttggtacttt tatttcactt ttattcttgt
ctatgtggat tagacaaatc 300acatagaagg taaatcacat cataatgaac
agcaaactgt ttgccagcat taaaagaaga 360agactgctta gatgcatgtc
actgatgaga aaataacttt aaacgcacac aagacggcac 420gtaccccaac
gcagtgggga cgttgcattt gaactcaacg tcaggtcgat gtcaatgttc
480ctaatgatgt tacagcttga tgttatgcgg ggattatggt tgccatacct
gatgaataaa 540ggttcgacat tggattttgg tcgctttcca cctatgacat
cgttattgga cgtcaaaata 600aatttaggtc accacaacct atatttaacc
tgctgggcaa taactaaatg cactacagaa 660taaatgcatc agcttttcac
agcataatac aaaagctact tttcactcat actttgagta 720acatttttag
gcatgtattg atatttttac cagccctccc catacataat cgtatgttta
780acattagctt tgttagccgc tagcattact gagcttgtgc atgaaagcag
atttggagct 840gatgattgcc gtaccatgat ctcacacctt gacgattgcg
taatgctatt aaatgcccat 900atttcgtgtt gacttgcacg agaaatgaga
tgggaacatt tatcagtggt cattaaatac 960tatttttgtg ttagcttagc
tgcagttttt aactattgta attaagtagt ttttctcaga 1020tgtactttta
ctttcccttg agtacatttt ccttccttca acctgcagtc actactttat
1080agtcctgtga ttcctgtcca atcaaattgc taccttaaga catgggccat
ttataattgc 1140tgtcaaaaat atttacacgc attaacccag agatgatgga
tgtttactgt atgatgaccg 1200aagacgtcaa catggcgtta ggttgacgtt
tgtttagaaa tgaaaattag gttgacgtca 1260aacatccaat ctaaaatcat
atatcaatgt atgttacccc tatgacgtct atcagacgtt 1320tgtcattatt
tgacgttggt ttaagatgtt acacaaccta aatccaccaa atattaactt
1380acaatatcct tagatgctgg ctagactttg taatattaac atcttatgat
gttgtgtgcc 1440tgttacgttt acacacatgt aaattacatg tcactactta
ctactcttga gtacttttaa 1500atatttacaa ctgatacttt tactcgcact
tatgattttt cagtactctt tccactactg 1560cacatatggt ggagtttaga
gccataatct gtgcagaatt gtgtgtgtgc acattttcca 1620atatcaatac
agaaggaaac tgtgttccct gttcccttgt aaatctcaac aatgcaactg
1680ttcagctcag ggggaaaaat gccctgccag atccaaacgg ctggcaaaag
tgaatggaaa 1740aaagcctttc attaatgtga aagttgctgc gcgccccacc
cagataaaaa gagcagaggt 1800taacatgctc tctacggctg tccagccaac
cagatactga ggcagaaaca cacccgctgg 1860cagatggtga gagctacact
gtcttttcca gagtttctac tggaatgcct gtcctcaagt 1920ctcaagcctc
tccttgcatt ctctcattcc acctggggca aagccccagg ctgggtgtga
1980caacatttat cttaccactt tctctctgta cctgtctaac aggtagggtg
tgtgtgagag 2040tgcgtatgtg tgcaagtgcg tgtgtgtgtg agagcagtca
gctccaccct ctcaagagtg 2100tgtataaaat tggtcagcca gctgctgaga
gacacgcaga gggactttga ctctcctttg 2160tgagcaacct cctccactca
ctcctctctc agagagcact ctcgtacctc cttctcagca 2220actcaaagac
acaggatccg g 224181456DNADanio rerioTATA signal(1389)..(1394)misc
feature(1428)..(1453)Identical to the 5' MCK cDNAprimer
bind(1433)..(1456)MCK2 8gaattgcaaa gtcagagtaa taaaatgaaa ccaaaaaaca
tttttaaata tacttgtctc 60tgtggcttaa tcttggctga tgtgtgtgtg tgtgtgtgtg
tacttgacag ctgctagtga 120gcatgtgcac catgacaggc ctgttattca
cacttggtgc catgttggag actgttcggc 180cagctatagt tttcttcaca
gagtcctggg tcacctaatg tcacaaggaa gaaacatgtt 240acatgttaaa
atgtgacatt caaattgtag tgcattactt aacgaaacgc attacacaag
300ttacagctta aaagattgct agacagaaaa accagggagg ggttttccca
taatatccag 360tgagactcta ggagcgggaa cactaacagg cctccctgag
tgagaacatt gcatgtgcgc 420gtgacagaaa accagagatg gaaatacctt
cttttgaatt gcataattgc ttaaaagaag 480acacaacagg gatagttcac
ccaaaaaaca gaccattctt tttttctgtt gaacaaaaat 540taagatattt
tgaagaatgc ttaccgaata acttccatat ttggaaacta attacagtga
600aagtcaatgg gtcttccagc attttttcaa tataccttac tttgagttca
aaagaaaaac 660acatctcaaa taggtttgag gttgaataaa catttttcat
tttggggtgg actatcccta 720attatttgac acttaagatt tatagtaaat
cattttatag actttctccc cttattaaac 780atggttgaat ttatcttcat
gtttatgtct gggttgtgct tttttgaaaa gatttccctg 840tcaaatgttt
ttgtgtatgg ttggcgcaca atagactgaa ctggcctatc acacagactt
900tcataacaac tccagttgat gccctttcac cctcagtgta taaatatggc
gtctgacatg 960agcagattaa acacgacact gcaacaactt tacctgtaaa
aatacaaatt gagtttgcac 1020ccagaatcat gtggtgaacg aagcctacca
agagattttt gaaagccatc ggcctgacac 1080gcgcacttct gatatctgtg
gtatgtttgg caaaagtgct gctcagcctt tttagcatgg 1140cagatcctcc
acatcccatc acccctcctt caacctattc cctcctggaa agctatgtat
1200ggggcgggaa gtgtaaatgg atatgggaag gaaggggggc accacccaca
gctgccacct 1260catctaggat gcctggggcc taaattgaag cctttcttac
actaaacagg gcataagaga 1320ccagcgccag ccaatcataa ttcagtgagc
tctaaaatgg gccagccaat ggctgcaggg 1380gctagaggta tatatatcca
aatcaaactc ttcttgcttg ggtgacccct atttcggctt 1440ggtgaacagg atccgg
145692205DNADanio reriomisc feature(775)..(791)Identical to the 5'
ARP cDNAIntron(792)..(2152)misc feature(2153)..(2199)Identical to
the 5' ARP cDNAprimer bind(2179)..(2205)ARP2 9atctgtatta agaaacactt
aaaatatata tgcgttacga attaaaaaca aaacacgatc 60attttaattt gtgttgtata
attttacatt ttgtaagtat tatttttata aaaaatatat 120agaaataata
caaatttgtt tacagtattc ttagttattg caataaacga attttatata
180gaaagagaaa gagttttatt ataagatgtt caatttaaaa aatggcagaa
aatagaaaaa 240tgattgtcaa gatgataaaa gtcagtttag acaaaaaaat
aagatgaaaa acatcaaaat 300agataataaa gtgacttttt tgggcggacc
aaatttccct attaatggtc aattcattaa 360aatacattca ttaaaataaa
ggtattgcga tgaatttaga tgcacagtga ttttggttct 420gtgcagattt
ttggctgttg ttagaaggga tacatctgcg gccgaaagtt aacgggaact
480atttacattc tttgctatta aattatccat tatttgtatt ttattacccc
aaccgtaaac 540tcaaccctca cagtaatgta aaaatattat ttattgtttt
atagcgtcac agaatgatgc 600tatattgacc gcagctgtat cctttctaag
tgcgactgta caaatacgca ctgaccgtga 660cagacacgtg cattgaccaa
tcagcgcaca gatacgcatt ttccgcgcga ttctgattgg 720atgatcgact
gatactaata ttgtgccgct tcctttcgcg gcctctttct ttcacgcgtc
780cctaccgtga ggtaaggctg acgccgctct tgtggcggtt tcttaaaatg
tgttaataaa 840taacatcata agaggtcacg agaaggtcta cgtgtgttta
atatcagcgg cggttattat 900tatgcgttta aagcttgtgt aatgattttt
acagtaaaag ttagcactag cctgttagca 960caggcctcgt gcgccatgtg
tgacgcgacg ttttaatagc atcttatttg attttgatga 1020tccgattctg
atattaatca tatttatgcg taaaatgtgt gatgggtctg ctagtggaca
1080ttacatgcta gtacttgtgc tagtcggtcg atccacattg agatgttgcg
ctatttgcca 1140ttttaaaacc agttactctc attttagtga aatattctta
agccactaag ttaaaatttg 1200tcaatcacat ataattgtgt ttatgtttta
tttgagtcat cataccaggt aatagtttta 1260tttatattag tatgtacaat
ttggcataaa ctgccttcgg ttttgattga catctacttt 1320gtaaaggtaa
tcttaaaggg gtaaaggctc acccaaaaga caattcaccg tcaagtgttt
1380tcaaatctta tgagtttctt aatgaacatg gtatgttttg gagaaaactg
gaaaccaact 1440accataatac aaatacagga aaaatatact atagaagtcg
atggttacag gttttctgca 1500ttcaaaatat ctacacaagt gtttaatgga
aggaactcaa gtgatttgaa aagttaaggg 1560tgcataaatc agttttcatt
tgggtgagct gtctctaaac atttgattta gacacctcag 1620gcagtggtca
ccaagcttgt tcctgaaggg ccagtgtcct acagatttta gctccaaccc
1680taattaaaca cacctgaaca agctaatcaa ggtcttacta ggtatgtttg
aaacatccag 1740gcaggtgtgt tgatgcaaga tagagctaaa ccctgcaggg
acaatggccc aacaggattg 1800gtgacccctg cctcaagcca tcacaaatgc
attatggtat taagaaatgt gcaggttcag 1860ttatggacag gctgttgcag
tgcttgttcg tcgttcccac tgcacaaatg aacatgattc 1920cttctatccc
tgtctgtctg catctcatga cttgcaggga cgctggtctc agacacgttt
1980atagcagtaa atcaaataca atagtgctct gattatcttt aaatatttga
aagcttataa 2040taggcaacca aattacctgg aaacagttta caaacagtaa
ttcatatttt gtcatttaat 2100aagatgcaca caaggcaggt gtaaaagtat
tgcttgtgtt tgtaatcctc agattttaca 2160accttgtctt taaaccggct
gttcaccgat ccttggaagg gatcc 22051024DNAArtificial
SequenceDescription of Artificial Sequence Cytokeratin - gene
specific primer 10cgctggagta agagatagac ctgg 241126DNAArtificial
SequenceDescription of Artificial Sequence Cytokeratin gene
specific primermisc feature(1)..(6)Introduced for restriction
sitemisc feature(3)..(8)BamHI site 11ccggatcctg tgtctttgag ttgctg
261224DNAArtificial SequenceDescription of Artificial Sequence
Muscle creatine kinase gene specific primermisc
feature(3)..(8)BamHI site 12ccggatcctt gggatcagat cctg
241324DNAArtificial SequenceDescription of Artificial Sequence
Muscle creatine kinase gene specific primermisc
feature(1)..(3)Introduced for restriction sitemisc
feature(3)..(3)BamHI site 13ccggatcctg ttcaccaagc cgaa
241425DNAArtificial SequenceDescription of Artificial Sequence
Acidic ribosomal protein PO gene specific primer 14tagttggact
tccacgtgcc ctgtc 251526DNAArtificial SequenceDescription of
Artificial Sequence Acidic ribosomal protein PO gene specific
primermisc feature(1)..(7)Introduced for restriction sitemisc
feature(1)..(6)BamHI site 15ggatcccttc caaggatcgg tgaaca
261651DNAArtificial SequenceDescription of Artificial Sequence
Oligonucleotide for linker used in linker-mediated PCR 16gttcatcttt
acaagctagc gctgaacaat gctgtggaca agcttgaatt c 511710DNAArtificial
SequenceDescription of Artificial Sequence Oligonucleotide for
linker used in linker-mediated PCRmisc feature(10)..(10)n is a
dideoxycytidinemisc_feature(10)..(10)n is a, c, g, or t
17gaattcaagn 101821DNAArtificial SequenceDescription of Artificial
Sequence linker specific primer 18gttcatcttt acaagctagc g
211920DNAArtificial SequenceDescription of Artificial Sequence
linker specific primer 19tcctgaacaa tgctgtggac 20201392DNADanio
rerioprimer bind(6)..(28)M2primer
bind(23)..(45)M1CDS(42)..(551)polyA signal(797)..(802)polyA
signal(1351)..(1357) 20ctcttcttga tcttcttaga cttcacacat accgtctcga
c atg gca ccc aag aag 56 Met Ala Pro Lys Lys 1 5gcc aag agg agg gca
gca gga gga gag ggt tcc tcc aac gtc ttc tcc 104Ala Lys Arg Arg Ala
Ala Gly Gly Glu Gly Ser Ser Asn Val Phe Ser 10 15 20atg ttt gag cag
agc cag att cag gag tac aaa gag gct ttc aca atc 152Met Phe Glu Gln
Ser Gln Ile Gln Glu Tyr Lys Glu Ala Phe Thr Ile 25 30 35att gac cag
aac aga gac ggt atc atc agc aaa gac gac
ctt agg gac 200Ile Asp Gln Asn Arg Asp Gly Ile Ile Ser Lys Asp Asp
Leu Arg Asp 40 45 50gtg ttg gcc tca atg ggc cag ctg aat gtg aag aat
gag gag ctg gag 248Val Leu Ala Ser Met Gly Gln Leu Asn Val Lys Asn
Glu Glu Leu Glu 55 60 65gcc atg atc aag gaa gcc agc ggc cca atc aac
ttc acc gtt ttc ctc 296Ala Met Ile Lys Glu Ala Ser Gly Pro Ile Asn
Phe Thr Val Phe Leu70 75 80 85acc atg ttc gga gag aag ttg aag ggt
gct gac ccc gaa gac gtc atc 344Thr Met Phe Gly Glu Lys Leu Lys Gly
Ala Asp Pro Glu Asp Val Ile 90 95 100gtg tct gcc ttc aag gtg ctg
gac cct gag ggc act gga tcc atc aag 392Val Ser Ala Phe Lys Val Leu
Asp Pro Glu Gly Thr Gly Ser Ile Lys 105 110 115aag gaa ttc ctt gag
gag ctt ttg acc act cag tgc gac agg ttc acc 440Lys Glu Phe Leu Glu
Glu Leu Leu Thr Thr Gln Cys Asp Arg Phe Thr 120 125 130gca gag gag
atg aag aat ctg tgg gcc gcc ttc ccc cca gat gtg gct 488Ala Glu Glu
Met Lys Asn Leu Trp Ala Ala Phe Pro Pro Asp Val Ala 135 140 145ggc
aat gtt gac tac aag aac atc tgc tac gtc atc aca cac gga gag 536Gly
Asn Val Asp Tyr Lys Asn Ile Cys Tyr Val Ile Thr His Gly Glu150 155
160 165gag aag gag gag taa acaaccttgg aatagaggaa acgaagagaa
gaacatgcat 591Glu Lys Glu Glucctcacagct taatctccag tctgttgtct
ggccttctct aacttttgtt tttccttcct 651ccctttcttg ctttctacca
tcgttgttac tccaagcact tacactctcc atcttaccaa 711agacttgtct
cgctgggact gaattgggag ggtggagagg aacacgacca cagtgtctgt
771cgagtgggga catgggattg ttttcaataa aatgaacatc atttctgtat
ctctcacatt 831ctctctttct ctctgtttct cactcattac ccacaacccc
tctctttcat ttcagtcaag 891cttgcatgta agtcgctgct tcttctgctg
cagtcttagg agttgaaacg aaggcatcta 951tagtttgggg ctgaaacatc
tctctagatc aatgtggaag agtgctcact ctgaggggga 1011aagaagcacg
atggagtgat ctcactctat aatagaggaa ccagtcatca ttctcatttc
1071ctcctctggt ggttgactaa aaagagaaag agaaaatgag ggttttgtgc
tgagtgagtt 1131tagcctccta aaagcgatgc cgagctcatc acagagggag
tgagagggac agaccatcct 1191aggaagagag gagagcaggg actgaaagaa
aacataacct cttcactccc cctctcccct 1251cctcttctct atttctctgt
ccatcttttc ttttttcttt tttctttttt gctttctgca 1311tctgggcctg
ctttgctctg ccaaacctct cctgtaacca ataaaaagac acaaactgtg
1371aataaaaaaa aaaaaaaaaa a 139221169PRTDanio rerio 21Met Ala Pro
Lys Lys Ala Lys Arg Arg Ala Ala Gly Gly Glu Gly Ser1 5 10 15Ser Asn
Val Phe Ser Met Phe Glu Gln Ser Gln Ile Gln Glu Tyr Lys 20 25 30Glu
Ala Phe Thr Ile Ile Asp Gln Asn Arg Asp Gly Ile Ile Ser Lys 35 40
45Asp Asp Leu Arg Asp Val Leu Ala Ser Met Gly Gln Leu Asn Val Lys
50 55 60Asn Glu Glu Leu Glu Ala Met Ile Lys Glu Ala Ser Gly Pro Ile
Asn65 70 75 80Phe Thr Val Phe Leu Thr Met Phe Gly Glu Lys Leu Lys
Gly Ala Asp 85 90 95Pro Glu Asp Val Ile Val Ser Ala Phe Lys Val Leu
Asp Pro Glu Gly 100 105 110Thr Gly Ser Ile Lys Lys Glu Phe Leu Glu
Glu Leu Leu Thr Thr Gln 115 120 125Cys Asp Arg Phe Thr Ala Glu Glu
Met Lys Asn Leu Trp Ala Ala Phe 130 135 140Pro Pro Asp Val Ala Gly
Asn Val Asp Tyr Lys Asn Ile Cys Tyr Val145 150 155 160Ile Thr His
Gly Glu Glu Lys Glu Glu 165222054DNADanio
rerioenhancer(142)..(148)E-box, canntgenhancer(452)..(457)E-box,
canntgenhancer(523)..(532)Potential MEF2 binding site,
yta(w)4tarenhancer(606)..(615)Potential MEF2 binding site,
yta(w)4tarenhancer(697)..(706)Potential MEF2 binding site,
yta(w)4tarenhancer(1095)..(1100)E-box,
canntgenhancer(1278)..(1283)E-box,
canntgenhancer(1362)..(1367)E-box,
canntgenhancer(1385)..(1390)E-box,
canntgenhancer(1490)..(1499)Potential MEF2 binding site,
yta(w)4tarenhancer(1640)..(1649)Potential MEF2 binding site,
yta(w)4tarenhancer(1956)..(1965)Potential MEF2 binding site,
yta(w)4tarTATA signal(1983)..(1989)Transcription start
site(2012)..(2012)misc feature(2027)..(2054)Identical to the 5'
MLC2f cDNAprimer bind(2032)..(2054)M2 22tgcatgcctg gcaggtccac
tctagaggac tactagtcat atgcgattct gaacaatgct 60ggaatgagcc accaactcat
ccagtgtatt accctacact gggaaacacc caaatctgtc 120tgttatattt
gtgcatatac attagattag aagctgtcac tgcggtggta ccttttcaaa
180ttgatacctc aaaagtatat attagtgcct tttaggtact aatatatacc
cttgaggttt 240tcatttggaa aggtaccacc ccagtgacag aaatctggag
cttatttaac aaaataactt 300tatttatatg ttattgaaaa atattaaata
agcaaaacaa tggaaaaaaa ttagttcaaa 360atttagcttt atttaaattg
ttttatcttt aatatagctg tttaataaat ctgttttgtt 420actgagagat
ggagaaaaat attcattttc ctgtaattat ctgtttttct aggtactgta
480caagcaggag caaaacaagc cgacagactc gggaatgcac aacaaactca
aggggggcaa 540gagagcaagg agcgctcaag attgtttagc ctgccttccc
aaaaaaaaac tgtcttaagc 600caaccactca gagggctgta gtgtgctgac
cgtgcttgtc cacagggcag cttcccacaa 660gtgaggtcat aggtcgatcg
gcagagagag atgggcatgg ccatgtggac gggtgtggtg 720actatactag
gaaaagcatt aaaacctatt aagacaccag aacgtcctct tatatatcag
780tcattggctc aaaaatctct ggattgaaat atccaacaag taatcctgca
agataagcca 840ggagggagtt gcgtcccctt tagactcagt atgtgattgt
atgaagctca aacagtccct 900gtggacagct tgaattcaat tcgccacaga
ttttatgcag cggatgccca tccagttgca 960ttttaaatta atatttttaa
taggaagcta tcagtacact ctcagaaata aatggtccgc 1020aggtacatat
ttgtacttaa agggtccata aaaaatttta agagaaacac ttttgtactt
1080tattatggac ctttaaggta caaattttta ctcacgccct ttatttctga
gagtgaagct 1140atgataacgg tccaaaaact actacaccca caaatttata
aacaggggaa aatcaagaga 1200atttgtaggt tgtaattttt ttgttgcaat
caattttgtg actaaaatat tattttaata 1260taaatgcacc aaaatacatt
gcctatattc aaaatgggct gtactcaatt actctaagca 1320aaataatgct
aatcttaaac aattttggaa acaggatatc aaattagtct aaagaaagaa
1380aacagtgact gatgaattag acaagaaaaa tattttggtc accacagctg
ttccttatgc 1440ctcaaatttc tcttcatgag ggtccaacat catctaaaaa
ctgggaaaaa ggggtaatta 1500atggcacctc acagtcactg aagtgaccgg
agagagagag agagagagag agtgctgaat 1560ggggcacttg aaccgaaatc
ttacagcatc ttcgattagg gctgatttga aataagggtt 1620ccagggcgtg
aacaaatatg aacaacataa ccatcaggat ctatcactgc aaccctcccc
1680gtattgatct gctgctaatc taactttagg ggctacagct cattcatttc
aaattgagtt 1740tacgtcccca tgtccttatt agacaacgcg agacatgcag
gccgctgcca tcagtatcag 1800attcatccca ttccaagact ccaatagcta
tttctgagca ctgtaagatg atagtacatc 1860ccagccggtg tccctccatc
actttccccc tacctcatag tttttcctct ttctctctcg 1920gtctgctatt
tcccaaacct cacttaaggt tgggtctata attagcaagg ggccttcgtc
1980agtatataag cccctcaagt acaggacact acgcggcttc agacttctct
tcttgatctt 2040cttagacttc acac 20542323DNAArtificial
SequenceDescription of Artificial Sequence MLC2F gene specific
primer Ml 23ccatgtcgag acggtatgtg tga 232423DNAArtificial
SequenceDescription of Artificial Sequence MLC2F gene specific
primer M2 24gtgtgaagtc taagaagatc aag 23
* * * * *